| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pacific Biosciences of California, Inc.$1.39
0 (0%)
Market Cap
378.93 M
EPS
-0.43
P/E Ratio
-
Value Trade
10.70 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
37.18 M
R&D Expenses
19.61 M
Operating CF
-44.69 M
Total Assets
782.37 M
Total Liabilities
780.00 M
Equity
2.37 M
D/E Ratio
12,345
0.83 %
Week
-30.68 %
1 Month
-26.28 %
3 Month
-34.05 %
6 Month
-95.39 %
5 Year
-92.61 %
All Time
Cash Data
Cash Position
275.96 M
Monthly Burn
14.90 M
Runway
15.8 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
7.93 M
52 Week Range
0.85 - 2.73
% held by Insiders
7.71 %
% held by Institutions
52.41 %
Enterprise Value
806.34 M
Total Shares
310.60 M
Short %
16.13 %
Float Shares
249.41 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | unexplained subfertility and recurrent pregnancy loss | — | 2026-05-11 | participants: 96; couples: 47; individuals: 2; genomic findings: approximately one in 10 couples; likely diagnostic findings: 4.8% of individuals Read More | HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss Read More | |
— | unexplained subfertility and recurrent pregnancy loss | — | 2026-05-11 | participants: 96; couples: 47; individuals: 2; genomic findings: approximately one in 10 couples; likely diagnostic findings: 4.8% of individuals Read More | HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss Read More | |
— | unexplained subfertility and recurrent pregnancy loss | — | 2026-05-11 | participants: 96; couples: 47; individuals: 2; genomic findings: approximately one in 10 couples; likely diagnostic findings: 4.8% of individuals Read More | HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PACB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PACB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PACBPacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
PacBio will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will feature a fireside chat with management, aimed at engaging investors. A live webcast will be available, with a replay accessible for 30 days post-event. PacBio specializes in advanced sequencing solutions for various research applications.
Read more →PACBPacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PacBio has announced that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on August 5, 2026. The call is set to take place at 4:30 p.m. Eastern Time and will be accessible via webcast. This event reflects the company's commitment to keeping investors informed about its financial performance.
Read more →PACBFDA draft guidance highlights the growing importance of long-read sequencing for genome editing safety assessment
The FDA's draft guidance highlights the significance of long-read sequencing in assessing genome editing safety. It emphasizes the need for comprehensive characterization of both intended and unintended genomic outcomes, particularly for larger structural alterations. PacBio's HiFi sequencing technology is positioned to meet these regulatory expectations by providing accurate and detailed genomic data.
Read more →PACBPowered by PacBio:<br /> Selected publications from April – June 2026
The article highlights recent publications showcasing advancements in genomics, particularly the role of long-read sequencing in enhancing genomic analysis. Key studies include the 1000 Chinese Pangenome project, which provides a significant resource for medical genetics, and a clinical study demonstrating the effectiveness of HiFi whole-genome sequencing in reproductive medicine. Additionally, a perspective on Near-Perfect Genome Sequencing outlines a future framework for genetic diagnostics.
Read more →PACB▲ +11.1%on this news
Rapid HiFi whole genome sequencing for time-critical genomic research
The article discusses the importance of rapid HiFi whole genome sequencing in neonatal intensive care units, emphasizing its potential to improve clinical outcomes for critically ill infants. Recent advancements in long-read sequencing technology allow for comprehensive genomic analysis without sacrificing speed. The new workflow reduces turnaround times significantly, enabling timely clinical decision-making. This approach aims to bridge the gap between speed and thoroughness in genomic research.
Read more →PACBExploring the epigenome of Earth’s biodiversity: From CHG and CHH methylation to Fiber-seq
The article discusses advancements in understanding the epigenome through HiFi sequencing, emphasizing the importance of DNA methylation and chromatin architecture in regulating gene expression. It highlights new methods like HiFiMeth and Fiber-seq that enable researchers to analyze epigenetic modifications across various plant and animal species. These innovations promise to streamline workflows and enhance the study of genetic variation and development.
Read more →PACBThe practical questions clinical research labs consider when adopting HiFi sequencing
The article discusses the practical considerations for clinical laboratories adopting HiFi sequencing. It highlights the accuracy and efficiency of HiFi whole genome sequencing (WGS) and its potential to improve diagnostic outcomes. Expert insights from a panel of laboratory leaders provide guidance on validation, operational integration, and the benefits of consolidating assays. The growing body of research supports HiFi sequencing as a valuable tool in clinical settings.
Read more →PACBThe microbial world is everywhere. Long-read sequencing is finally allowing us to see it clearly.
The article discusses the advancements in microbial genomics enabled by PacBio's HiFi long-read sequencing technology. This method provides complete and accurate microbial genome assemblies, addressing limitations of traditional sequencing techniques. Researchers are gathering at ASM Microbe to explore these innovations, which enhance our understanding of microbial diversity and its implications for health and agriculture.
Read more →PACB▲ +14%on this news
The pivotal decisions that make for great sequencing data
The article discusses the critical decisions researchers face when designing sequencing experiments, particularly with long-read sequencing. It highlights the importance of selecting the right technology and method, as well as proper sample preparation to ensure data quality. The introduction of SPRQ-Nx chemistry is noted for significantly lowering costs and enhancing capabilities in sequencing. A resource bundle is offered to assist researchers in making informed choices.
Read more →PACBPacBio to Participate in the Jefferies Global Healthcare Conference 2026
PacBio will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York and will be accessible via a live webcast. PacBio is known for its high-quality sequencing solutions aimed at resolving complex genetic issues across various research applications.
Read more →PACB▲ +5%on this newsshared move
Publication spotlight: How one HiFi sequencing assay can bring clarity to unexplained infertility
The HiFi Solves Sub-fertility Consortium has initiated a study to explore the use of long-read whole genome sequencing in understanding unexplained infertility and recurrent pregnancy loss. The study involved 84 individuals across Asia-Pacific and demonstrated that HiFi sequencing could identify clinically relevant genetic findings, potentially reducing the emotional and logistical burdens of traditional testing methods. This approach aims to provide a more comprehensive genomic view, which could lead to better insights and faster diagnoses for couples facing fertility challenges.
Read more →PACB▲ +5%on this newsshared move
PacBio to Participate in the Jefferies Global Healthcare Conference
PacBio will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York and will be accessible via a live webcast. This participation highlights PacBio's commitment to sharing advancements in sequencing technology with the healthcare community.
Read more →PACBBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
Blank Bio has announced a $7.2 million seed financing and a strategic collaboration with PacBio to enhance RNA foundation models for precision oncology. The partnership aims to generate high-resolution long-read RNA sequencing data from patient tumor samples, which will improve patient-level predictions and biomarker discovery. The funding will support ongoing model development and collaborations in the oncology field.
Read more →PACBThe power of one: How assay consolidation and menu expansion reshape sequencing economics
The article discusses how assay consolidation and menu expansion in HiFi long-read sequencing enhance laboratory efficiency and reduce costs. By utilizing a single comprehensive assay, laboratories can streamline workflows and improve turnaround times. The introduction of SPRQ-Nx chemistry further lowers sequencing costs while maintaining performance. This integrated approach supports a wider range of applications, ultimately reshaping sequencing economics.
Read more →PACBHiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
PacBio announced a significant study from the HiFi Solves Sub-fertility Consortium, utilizing HiFi long-read sequencing to investigate unexplained subfertility and recurrent pregnancy loss. The study involved 96 participants across Asia-Pacific and demonstrated the ability of HiFi sequencing to provide comprehensive genetic insights. Findings suggest that this approach could reduce the need for sequential testing and support informed reproductive counseling.
Read more →PACB▼ -14.5%on this newsshared move
Long-read sequencing is not the trade-off it used to be: These are the 5 questions that show why
The article discusses the advancements in HiFi long-read sequencing, emphasizing its ability to resolve complex genomic structures with high accuracy and lower costs. It highlights the advantages over traditional short-read methods, particularly in capturing methylation data and full-length isoforms. The author encourages labs to reconsider their sequencing choices to leverage these benefits.
Read more →PACBPacBio Announces First Quarter 2026 Financial Results
PacBio reported its financial results for Q1 2026, highlighting a significant increase in consumable revenue due to the growing adoption of its HiFi technology. The company has expanded its beta program and secured a major collaboration with Basecamp Research for the Trillion Gene Atlas. However, instrument revenue fell short of expectations, impacting overall financial performance.
Read more →PACB▲ +8.2%on this news
Improving HiFi sequencing accuracy with Google DeepConsensus and AlphaEvolve
PacBio and Google AI have enhanced HiFi sequencing accuracy through DeepConsensus and AlphaEvolve. The Revio system's upcoming updates will reduce genome sequencing costs and improve read quality. These advancements enable researchers to generate more accurate genomic data efficiently, fostering significant progress in genomics and related fields.
Read more →PACBHiFi multiomics reveals how biology shapes life on Earth
Recent advancements in multiomics and HiFi sequencing are enhancing our understanding of biodiversity and genomic functions across various species. Studies from institutions like the Wellcome Sanger Institute and UC Davis showcase how these technologies reveal mutation patterns, structural variations, and gene regulation. This integrated approach is pivotal for conservation efforts and ecological monitoring.
Read more →PACBFrom genome to therapy: How HiFi long-read sequencing is helping to accelerate next-generation cancer drug research and development
The article discusses the advancements in cancer drug development through HiFi long-read sequencing technology. This method provides a comprehensive understanding of genomic variations, enabling the identification of therapeutic targets and biomarkers. It enhances the detection of complex structural variations and supports the development of personalized therapies, including CAR-T and cancer vaccines. The integration of genomic and epigenetic data is emphasized as crucial for advancing precision oncology.
Read more →PACBPacBio to Report First Quarter 2026 Financial Results on May 7, 2026
PacBio has announced that it will hold a conference call on May 7, 2026, to discuss its financial results for the first quarter of 2026. The call is scheduled for 4:30 p.m. ET and will be accessible via webcast. The company continues to focus on providing advanced sequencing solutions for various research applications.
Read more →PACB▼ -8.2%on this news
How SPRQ-Nx enables a single genomic workflow to help reduce costs in cancer detection techniques
The article discusses how SPRQ-Nx enables a single genomic workflow that consolidates multiple cancer detection assays, significantly reducing costs and turnaround times. By utilizing HiFi sequencing, the new approach minimizes the complexity of traditional testing methods, providing a comprehensive genomic view upfront. This innovation not only lowers the financial burden on patients but also enhances the overall experience for clinicians and labs.
Read more →PACB▲ +6%on this newsshared move
Sequencing 101: the evolution of DNA sequencing tools
The article discusses the evolution of DNA sequencing technologies, highlighting the advancements from Sanger sequencing to PacBio's HiFi sequencing. It emphasizes the advantages of long-read sequencing, including its ability to produce high-accuracy reads and its growing accessibility in research. Recent innovations have improved cost efficiency and expanded applications, particularly in clinical settings.
Read more →PACBPowering cancer testing research with HiFi whole genome sequencing and targeted panels
The article discusses the advancements in cancer testing through HiFi whole genome sequencing (WGS) and targeted panels. It highlights the importance of accurate sequencing in detecting complex genomic features and the benefits of using HiFi technology for both comprehensive and focused cancer insights. Partnerships with industry leaders further enhance the implementation of these technologies in clinical settings.
Read more →PACBPowered by PacBio:<br /> Selected publications from January – March 2026
PacBio's latest quarterly publication showcases significant advancements in HiFi sequencing across various research areas, including ALS, cancer, and rare diseases. The studies highlight the technology's ability to uncover complex transcript biology and improve diagnostic outcomes. Researchers are leveraging these insights to enhance understanding of disease mechanisms and develop new therapeutic targets.
Read more →PACBHow HiFi metagenomic sequencing is powering AI-driven discovery with Basecamp Research
Basecamp Research has selected PacBio HiFi sequencing for its Trillion Gene Atlas initiative, emphasizing the importance of high-quality biological data for AI in drug discovery. The project aims to generate a diverse dataset from 100,000 samples across 30 countries, enhancing AI models' understanding of biology. HiFi sequencing's accuracy and long-read capabilities are crucial for capturing complex genomic structures, paving the way for improved therapeutic innovations.
Read more →PACB2025 Immunology and Immunotherapy SMRT Grant winners announced
ClareoBio has announced the winners of the 2025 PacBio Immunology and Immunotherapy SMRT Grant, recognizing four innovative research proposals aimed at enhancing immune profiling. The grant supports projects utilizing the ProfilAIR assay powered by PacBio HiFi sequencing. These studies focus on various aspects of immunology, including B-cell receptor dynamics and maternal-infant immune interactions.
Read more →PACB▲ +5.3%on this news
Cancer genomics myths revisited: How advances in HiFi sequencing keep strengthening the evidence
The article discusses the evolution of cancer genomics, particularly focusing on the advancements in HiFi sequencing technology. It debunks several myths surrounding long-read sequencing, highlighting its affordability, compatibility with FFPE samples, and its ability to capture complex transcriptomic data. The article emphasizes the clinical relevance of HiFi sequencing in resolving previously unexplained cancer cases, showcasing its growing importance in modern genomics.
Read more →PACB▼ -5.9%on this news
What a clearer view of epigenetics can mean for cancer research
Recent advancements in HiFi sequencing technology are revolutionizing cancer research by enabling the detection of multiple epigenetic marks directly from genomic DNA. The new SPRQ-Nx chemistry improves the performance of 5mC detection and introduces 5hmC detection, allowing researchers to gain deeper insights into tumor biology and gene regulation. This technology facilitates a comprehensive view of genetic and epigenetic variations, crucial for understanding cancer development.
Read more →PACBPacBio Announces the Appointment of Chris Gibson to the Board of Directors
PacBio has appointed Dr. Christopher Gibson to its Board of Directors. Dr. Gibson, co-founder of Recursion, brings extensive experience in AI-driven drug discovery and data analytics. His leadership is expected to support PacBio's vision of integrating sequencing technologies with advanced analytics, enhancing their capabilities in biological research and healthcare.
Read more →PACBBeyond the Bench: Exploring the terrain of repeat expansion diseases with HiFi sequencing
The article discusses the 'Beyond the Bench' series, focusing on Dr. Birgitt Schuele's research on repeat expansion diseases, particularly Spinocerebellar Ataxia Type 10 (SCA10). It emphasizes the importance of HiFi sequencing in accurately profiling repeat expansions, which are linked to various neurological disorders. The series aims to connect scientific research with personal narratives and community engagement.
Read more →PACB▲ +9.2%on this news
Rare disease month: Activating the community through hackathons
The article discusses the role of hackathons in advancing rare disease research by bringing together experts to collaboratively solve complex cases. These events compress the diagnostic process, allowing for quicker insights and solutions. Recent hackathons, such as those organized by the Wilhelm Foundation, have successfully identified definitive findings for numerous participants, showcasing the potential of high-quality genomic data in clinical settings.
Read more →PACB▲ +5.1%on this newsshared move
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
PacBio has partnered with DNAstack to create the first global federated dataset of HiFi whole genome sequencing data. This initiative, part of the HiFi Solves Global Consortium, allows secure international research while keeping sensitive data under institutional control. The collaboration aims to enhance rare disease research by connecting over 10,000 genome sequences from institutions across 15 countries, improving the accuracy of variant detection and accelerating discoveries.
Read more →PACBRadboud UMC research highlights promise of HiFi long-read sequencing to match standards of care in rare disease genomics
Radboud University Medical Center's recent study highlights the effectiveness of HiFi long-read whole genome sequencing (WGS) in rare disease diagnostics. The study demonstrated a 96.4% concordance with standard testing methods, suggesting HiFi sequencing could serve as a first-line test. This approach may improve diagnostic clarity and reduce the need for multiple tests, benefiting families seeking answers. The findings support a shift towards integrating HiFi sequencing into routine clinical practice.
Read more →PACBPacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner
PacBio has partnered with the iHope initiative to integrate its HiFi long-read whole-genome sequencing into iHope's global rare disease genomics program. This collaboration aims to improve diagnostic clarity for patients with rare genetic disorders by providing comprehensive genomic insights. The integration is set to begin in early 2026, enhancing the capabilities of iHope's extensive testing network.
Read more →PACBRare Disease Month: Taking a People-First approach in the global fight against rare disease
The article highlights the importance of a people-first approach in addressing rare diseases during Rare Disease Month. It shares stories from Thailand and Sweden, showcasing how advancements in genomic sequencing, like PacBio's HiFi technology, are improving diagnosis and treatment. The LIFE-Seq program aims to provide early genomic insights for newborns, while community events help families connect and support each other in their journeys.
Read more →PACBPacBio Announces Fourth Quarter and Full Year 2025 Financial Results
PacBio reported its financial results for Q4 and FY 2025, highlighting a revenue increase to $44.6 million in Q4 2025, up from $39.2 million in Q4 2024. Despite this growth, the company faced a significant net loss of $40.4 million in Q4 2025. The annual results also reflected an increase in net loss, totaling $546.4 million for the year, compared to a net loss of $309.9 million in 2024. The company emphasized its growth in consumables and strategic collaborations aimed at advancing genomic testing.
Read more →PACB▼ -12.1%on this news
How SPRQ-Nx enables affordable long-read whole genome sequencing without added complexity
The introduction of SPRQ-Nx has made long-read whole genome sequencing more affordable and accessible, reducing costs by up to 40% while maintaining high data quality. This technology allows for the reuse of SMRT Cells, enabling multiple sequencing runs without altering existing workflows. The datasets generated demonstrate consistent performance across human, plant, and animal genomes, making it suitable for larger studies.
Read more →PACBPacBio Completes Sale of Short-Read Sequencing Assets
PacBio has completed the sale of its short-read sequencing assets to Illumina for $48.1 million. This strategic move allows PacBio to concentrate on its long-read sequencing technology, which is anticipated to enhance growth opportunities. The transaction closed on January 30, 2026, and includes a non-exclusive license back to PacBio for certain intellectual property.
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On
Pacific Biosciences of California, Inc. has completed an asset sale to Illumina Cambridge Limited, receiving $50 million in cash and retaining a non-exclusive license for certain intellectual property. The transaction involved the sale of assets related to the company's short-read DNA sequencing technology. Following the asset sale, the company's pro forma financial statements reflect adjustments for the asset's impact on their financial position and operating results as of September 30, 2025. Despite the cash inflow, PacBio continues to experience significant net losses.
Read more →PACBBeyond the Bench: Advancing cancer transcriptomics with HiFi long-read RNA sequencing
The article discusses the PacBio Beyond the Bench video series, highlighting Dr. Santosha Vardhana's research on immune cell behavior in cancer. His work emphasizes the importance of single-cell RNA sequencing and HiFi long-read RNA sequencing in understanding cancer biology and immune responses. These advanced techniques allow for a more detailed analysis of RNA isoforms and their roles in cancer progression.
Read more →PACB▼ -7.4%on this news· ran to -20% by day 3shared move
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
PacBio has announced a quarterly conference call to discuss its fourth quarter and full year 2025 financial results, scheduled for February 12, 2026. The call will be accessible via webcast on the company's investor relations website. This event highlights PacBio's commitment to transparency and investor engagement.
Read more →PACB▲ +10.3%on this news
Publication spotlight: HiFi sequencing enables haplotype-specific chromatin mapping from single cells using DAF-seq
The article discusses a significant advancement in single-cell epigenomics through DAF-seq, a method developed by researchers at the University of Washington. This technique utilizes HiFi sequencing to achieve high-resolution chromatin mapping, allowing for detailed insights into gene regulation at the single-cell level. DAF-seq overcomes limitations of previous methods, enabling the study of chromatin architecture and protein interactions with unprecedented accuracy.
Read more →PACB2025 Epigenetics SMRT Grant Awardees
The 2025 Epigenetics SMRT Grant has been awarded to researchers focusing on chromatin structure and gene regulation. The winners, including Wen Shen and Gemma Carvill, will utilize Fiber-seq technology to explore critical aspects of gene regulation and chromatin dynamics. Their projects aim to advance understanding in cancer and neurodevelopmental disorders.
Read more →PACB▲ +6%on this news· ran to +17% by day 1shared move
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
PacBio reported preliminary unaudited revenue of $44.6 million for Q4 2025, marking a 14% increase year-over-year. The full year revenue reached $160 million, reflecting a 4% growth. The company attributes this momentum to strong sales of its Revio and Vega products and record consumables revenue. Looking ahead, PacBio anticipates further growth driven by real-world evidence and lower costs from its SPRQ-Nx technology.
Read more →PACB▲ +6%on this news· ran to +17% by day 1shared move
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
PacBio has announced that its HiFi whole-genome sequencing will be the primary method used to investigate Sudden Unexplained Death in Childhood (SUDC) in a research project involving 200 families. This approach aims to improve diagnostic yield by accurately detecting complex genetic variants. The initiative is supported by the SUDC Foundation and aims to provide families with clearer answers regarding the genetic factors contributing to SUDC.
Read more →PACB▲ +6%on this news· ran to +17% by day 1shared move
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
PacBio announced a strategic collaboration with the n-Lorem Foundation and EspeRare to advance precision therapies for ultra-rare genetic diseases. The partnership will utilize PacBio's long-read whole-genome sequencing technology to improve the design and feasibility of individualized antisense oligonucleotide therapies. This collaboration aims to enhance genomic understanding and accelerate the development of effective treatments for patients with rare genetic mutations.
Read more →PACBA year in review: HiFi in the Headline
In 2025, PacBio made significant strides in genomics with advancements in HiFi sequencing technology. Key developments included the introduction of the Ampli-Fi protocol for ultra-low DNA inputs and the launch of Fiber-seq for multiomics workflows. The company also expanded its PureTarget offerings, enhancing targeted sequencing solutions. These innovations are set to improve clinical research and diagnostics in genomics.
Read more →PACBPacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell
PacBio has launched CiFi, a novel method that integrates chromatin conformation capture with HiFi sequencing, enabling chromosome-scale genome assemblies from minimal input. Developed in collaboration with UC Davis, CiFi addresses limitations of traditional Hi-C methods by producing long, accurate reads that enhance chromatin interaction mapping. This innovation is expected to significantly benefit genome biology and biodiversity studies.
Read more →PACBMeet the winners of the 2025 long-read low-pass SMRT Grant for plant and animal sciences
The winners of the 2025 Long-read Low-pass SMRT Grant have been announced, recognizing two researchers for their innovative projects in plant and animal sciences. Benjamin Moran will explore coral bleaching genomics, while Kristina Black will investigate the genetic responses of Arctic bearded seals to environmental stressors. These projects highlight the potential of long-read sequencing technology in advancing biodiversity research.
Read more →PACBBeyond the Bench: <br />A series celebrating the people behind scientific progress
The article introduces 'Beyond the Bench,' a video series by PacBio that explores the daily lives of three scientists and their unique approaches to research. Dr. Santosha Vardhana, Dr. Andor Kiss, and Dr. Birgitt Schüle share their personal rituals and motivations that drive their scientific inquiries. The series aims to connect audiences with the human side of scientific discovery.
Read more →PACB▼ -8.4%on this news
Sequencing 101: A long-read sequencing starter guide for every career stage
The article introduces Sequencing 101 materials designed to assist individuals at various career stages in understanding long-read sequencing and HiFi technology. It provides tailored resources for grad students, bioinformaticians, principal investigators, and core facility directors, emphasizing the importance of data quality and effective workflows. Additionally, it includes support for grant applications to enhance funding opportunities.
Read more →PACBPowered by PacBio:<br /> Selected publications from November 2025
Recent publications highlight the impact of PacBio technology on human genomics research. Key studies include advancements in variant detection in paralogous genes, the introduction of the PangyPlot visualization tool for pangenome graphs, and a cost-effective HiFi assay for newborn screening. These innovations are paving the way for improved diagnostics and understanding of genetic diseases.
Read more →PACBPacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
PacBio will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The management will engage in a fireside chat at 11:30 AM ET in New York. A live webcast will be available for those unable to attend, with a replay accessible for 30 days post-event.
Read more →PACB▼ -9.1%on this newsshared move
How long-read sequencing informs the future of food from genome to table
PacBio highlights the role of HiFi sequencing in enhancing sustainable agriculture. As the Plant and Animal Genome Conference approaches, the company emphasizes how genomics aids in breeding, pest management, and germplasm recharacterization. These advancements contribute to more resilient food systems, benefiting both people and the environment.
Read more →PACB▲ +12.6%on this newsshared move
Publication spotlight: <br />First major study from the HiFi Solves EMEA consortium showcases the potential clinical power of a HiFi genome
The HiFi Solves EMEA consortium has published a pivotal study demonstrating the effectiveness of PacBio HiFi long-read genome sequencing in clinical diagnostics. The study achieved a 100% detection rate of known pathogenic variants across multiple laboratories, showcasing the technology's reliability and potential for widespread implementation. This advancement marks a significant step toward improving precision diagnostics in clinical genetics.
Read more →PACBPacBio to Present at Upcoming Investor Conferences
PacBio (NASDAQ: PACB) announced its participation in upcoming investor conferences, highlighting its commitment to engaging with the investment community. The company will provide live webcasts of the events, which will be available for replay for 30 days. PacBio is known for its advanced sequencing solutions that address various scientific research applications.
Read more →PACB▼ -6.3%on this newsshared move
How pairing EpiCypher’s Fiber-seq with HiFi sequencing delivers an all-in-one multiomic view
EpiCypher has launched the CUTANA Fiber-seq kit, which integrates with PacBio HiFi sequencing to provide a comprehensive view of chromatin structure and gene regulation. This innovative approach allows researchers to study genetic variants, DNA methylation, and protein interactions in a single assay. Fiber-seq addresses limitations of traditional methods, offering high-resolution insights into epigenetics and potential applications in disease research.
Read more →PACBPowered by PacBio:<br /> Selected publications from October 2025
The October 2025 edition of 'Powered by PacBio' highlights significant advancements in genomics research using PacBio's long-read sequencing technology. Key studies include a large-scale analysis of structural variants in the All of Us Research Program, findings on somatic mosaicism in Fragile X syndrome, and a comprehensive review of ALS genetics. These studies demonstrate the transformative potential of long-read sequencing in precision medicine.
Read more →PACB▼ -7%on this newsshared move
PacBio Announces Third Quarter 2025 Financial Results
PacBio reported its third quarter 2025 financial results, showing a GAAP gross profit of $15.9 million, up from $10.0 million in Q3 2024. The company achieved record consumable revenue and improved gross margins, while also reducing operating expenses. However, revenue fell slightly short of expectations, and the net loss remains significant at $38.0 million.
Read more →PACBHiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
PacBio announced a significant study from the HiFi Solves EMEA Consortium, showcasing that HiFi sequencing can accurately identify all known clinically relevant variants in a diverse cohort. The study validates the technology's potential for clinical utility, demonstrating its effectiveness in challenging genomic regions. This advancement could revolutionize clinical testing and rare disease diagnostics.
Read more →PACBDocument PacBio Announces Third Quarter 2025 Financial Results
PacBio announced its financial results for Q3 2025, with revenue decreasing to $38.4 million from $40.0 million in Q3 2024. Despite this decline, the company reported record consumable revenue and improved gross margins. The introduction of the SPRQ-Nx sequencing chemistry is expected to significantly reduce sequencing costs. However, total cash and investments saw a significant decline year-over-year.
Read more →PACB▼ -10.7%on this news· ran to -21% by day 3shared move
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
PacBio has announced that its Sequel II CNDx system has received Class III Medical Device Registration approval from the NMPA in China, marking the first regulatory clearance for a clinical-grade long-read sequencer. This approval enables comprehensive genomic testing for high-incidence genetic disorders, improving diagnostic capabilities in China. The system's high accuracy and long read lengths facilitate a complete genomic analysis in a single test.
Read more →PACBPublication spotlight:<br />Capturing the full picture of genome editing with custom PureTarget panels
The article discusses the advancements in genome editing using PureTarget panels, which enhance the detection of genetic mosaicism in CRISPR-Cas9 edited organisms. Researchers from Uppsala University demonstrated that PureTarget can accurately characterize diverse genetic variants without amplification bias. This method provides a clearer understanding of editing outcomes, crucial for verifying germline edits and their potential inheritance across generations.
Read more →PACBCustomer success story:<br /> How two University of Michigan cores use HiFi sequencing to cut costs, save time, and improve accuracy in transgenic models
The University of Michigan's Advanced Genomics Core and Transgenic Animal Model Core have collaborated to enhance genomic research through HiFi long-read sequencing. This partnership has improved accuracy in transgenic model characterization while reducing costs and time. The transition to HiFi sequencing has allowed researchers to move beyond traditional methods, fostering a more reliable approach to genome editing.
Read more →PACBLandmark All of Us study demonstrates HiFi sequencing as the key to uncovering disease variants
PacBio's HiFi sequencing technology has been showcased at ASHG, highlighting its role in the All of Us Research Program. A recent study indicates that traditional short-read sequencing misses many disease-associated structural variants. The research emphasizes the importance of HiFi sequencing in capturing comprehensive genomic data, particularly from underrepresented populations, paving the way for advancements in precision medicine.
Read more →PACBPacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
PacBio has announced advancements to its Revio and Vega platforms aimed at reducing genome sequencing costs and enhancing multiomic capabilities. The new SPRQ-Nx sequencing chemistry could lower costs to under $300 per genome, with beta testing starting in November 2025. The Vega system will also integrate these advancements, including rapid sequencing options and compliance features for regulated labs. These innovations aim to make HiFi sequencing more accessible for diverse research applications.
Read more →PACB▲ +14.1%on this newsshared move
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
PacBio's HiFi sequencing technology has been chosen as the primary platform for South Korea's National Pangenome Project, aimed at generating comprehensive reference genomes for the Korean population. This initiative, led by the Korea Disease Control and Prevention Agency, will integrate data into the global Human Pangenome Reference Consortium, enhancing insights into population-specific genetic variants. The project is expected to significantly advance precision diagnostics and therapeutic development.
Read more →PACBHow HiFi sequencing achieves scalable microbial genomics without compromise
PacBio's HiFi sequencing technology addresses the growing demand for high-resolution microbial data without compromising on cost or accuracy. It supports various applications, including whole genome sequencing and metagenomics, allowing researchers to choose from flexible library preparation options. This innovation enhances microbial genomics, making it accessible for public health, academic, and industrial applications.
Read more →PACB▲ +7.9%on this newsshared move
Long Life Family Study Taps PacBio HiFi Sequencing to Unlock Genetic and Epigenetic Clues to Exceptional Longevity
PacBio has been selected by the National Institute on Aging for the Long Life Family Study to utilize its HiFi sequencing technology. This initiative aims to analyze genomic and epigenomic data from up to 7,800 participants to explore the genetic factors contributing to exceptional longevity. The study has received $80 million in funding and is set to begin sequencing in Q4 2025.
Read more →PACB▼ -7.9%on this newsshared move
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
PacBio has announced an expanded partnership with seqWell to distribute the LongPlex Multiplexing Kit, which streamlines sample preparation for HiFi sequencing. This collaboration aims to enhance workflow options for researchers, enabling faster and more cost-effective data generation. The LongPlex kit is designed for high-throughput applications and is already being utilized by organizations like Veil Genomics.
Read more →PACBPowered by PacBio:<br />Selected publications from September 2025
In September 2025, various studies showcased the versatility of HiFi sequencing, revealing insights into human genomic imprinting, enhancing clinical diagnostic tools, and uncovering rare hemoglobin variants. Notably, research demonstrated improved diagnostic yields in pediatric patients and identified novel RNA isoforms that could impact cancer immunotherapy. These findings underscore the transformative potential of long-read sequencing in genetic research and clinical applications.
Read more →PACBHow PureTarget is modernizing research into carrier screening
PacBio has launched the expanded PureTarget portfolio, which modernizes carrier screening by utilizing HiFi long-read sequencing. This new approach consolidates multiple legacy methods into a single, comprehensive workflow, enhancing accuracy and efficiency. The PureTarget panels are designed to address the challenges of sequencing critical genes associated with inherited diseases, thereby supporting large-scale carrier screening initiatives.
Read more →PACBPacBio Enters High-Throughput Carrier Screening Market with Standalone HiFi Sequencing Assay for Challenging Genes
PacBio has launched an enhanced suite of PureTarget products for high-throughput carrier screening. Utilizing its HiFi sequencing technology, the new solutions allow laboratories to consolidate multiple assays into a single scalable test. This innovation addresses the challenges of testing difficult hereditary genes, thereby improving accessibility and efficiency in genetic screening.
Read more →PACBThe growing importance of carrier screening in genomics
Carrier screening is revolutionizing human health by identifying genetic risks before they manifest. It has evolved from targeted tests for specific populations to expanded carrier screening, which examines hundreds of genes simultaneously. This advancement allows for better-informed reproductive choices and enhances public health by reducing the burden of inherited diseases. Future developments aim to improve accuracy and streamline workflows in genetic testing.
Read more →PACB2025 Microbiome SMRT Grant Awardees
PacBio has announced the winners of the 2025 Microbiome SMRT Grant, awarding four researchers for their innovative projects in microbiome and metagenomics research. The selected projects focus on critical areas such as childhood growth stunting, colorectal cancer, and forensic applications of microbiome data. These initiatives aim to leverage high-accuracy sequencing technology to uncover new insights into human health.
Read more →PACBPowered by PacBio: <br/>Selected publications from August 2025
The article highlights recent publications showcasing the advancements of HiFi sequencing in clinical genomics. Key studies demonstrate its effectiveness in low-input cancer sample sequencing, comprehensive methylation profiling, and the resolution of complex repeat expansions. Additionally, HiFi sequencing reveals novel isoforms relevant to cancer immunotherapy, emphasizing its role in precision medicine.
Read more →PACBPacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow
PacBio has partnered with EpiCypher to integrate the CUTANA Hia5 enzyme into its Fiber-seq workflow. This collaboration aims to enhance the understanding of chromatin biology at single-molecule resolution. The Fiber-seq assay allows researchers to measure chromatin accessibility and DNA variations simultaneously, providing deeper insights into gene regulation and its implications for health and disease.
Read more →PACBLooking to make sense of your research? There’s HiFi for that
The article introduces 'There’s HiFi for that,' a new initiative aimed at improving genomic research through HiFi sequencing. This approach offers long, accurate reads that enhance data reliability and clarity, addressing common frustrations in sequencing. The initiative includes resources like a starter pack and opportunities for conference attendance, promoting confidence in genomic analysis.
Read more →PACBFast-track biopharma breakthroughs with HiFi long-read sequencing
The article discusses the advantages of HiFi long-read sequencing in biopharmaceutical research. This technology enhances accuracy, reduces development timelines, and supports the discovery of new therapeutic targets. A webinar on August 26 will showcase real-world applications of HiFi sequencing in advancing research. The integration of genomic, transcriptomic, and epigenomic data is emphasized as crucial for innovation.
Read more →PACBSequencing 101: How multiplexing with long-read sequencing makes genomic research faster, cheaper, and smarter
The article discusses the advantages of multiplexing in genomic sequencing, particularly using PacBio HiFi systems. Multiplexing allows multiple samples to be sequenced in parallel, improving efficiency and reducing costs. It involves barcoding samples for identification and demultiplexing after sequencing. The article highlights various applications and the importance of accurate barcoding and sample representation.
Read more →PACB▲ +7.1%on this news
Powered by PacBio:<br /> Selected publications from July 2025
In July 2025, several studies showcased the significant role of HiFi sequencing in autism research and brain evolution. Researchers utilized long-read data to uncover previously inaccessible genomic regions, leading to the identification of rare genetic variants and insights into human-specific gene expansions. These advancements highlight the potential of HiFi sequencing to enhance our understanding of genetic variation and its implications for neurodevelopmental disorders.
Read more →PACB▼ -8.7%on this newsshared move
Document PacBio Announces Second Quarter 2025 Financial Results
PacBio reported its financial results for the second quarter of 2025, demonstrating revenue growth to $39.8 million compared to $36.0 million in the same quarter of 2024. The company reported improved GAAP gross profit reflecting better performance and reduced operating expenses, resulting in a lower net loss. Notable updates include contributions to the 1000 Genomes Long Read Project and expansion in clinical settings in China. Despite these positive developments, PacBio faced continued net losses and a decrease in cash reserves.
Read more →PACB▼ -7.4%on this news
Customer success story: <br />How Dr. Ibrahim Bitar is doubling his research impact while leading the future of European genomics from the Czech Republic
Dr. Ibrahim Bitar, an Assistant Professor at Charles University and CEO of Gene Omics, is enhancing microbial genomics in Central Europe through affordable HiFi long-read sequencing. His innovative approach, utilizing the Vega and Revio systems, is empowering researchers and improving research quality. Bitar emphasizes the importance of making advanced sequencing technology accessible to all.
Read more →PACB▼ -8.9%on this news
Publication spotlight: How Kinnex long-read RNA sequencing wins out over Illumina for transcript-level quantification
A recent study highlights Kinnex long-read RNA sequencing's advantages over Illumina's short reads for transcript-level quantification. Conducted by researchers from the University of Zurich and University of Virginia, the study shows Kinnex provides more reliable and accurate detection of complex transcripts. The findings suggest Kinnex is a practical choice for projects requiring detailed transcript analysis.
Read more →PACB▼ -6.7%on this news
How long-read sequencing uncovers hitchhikers of the genomic galaxy in parasitic fungi
A study from the University of Kiel reveals that transposable elements (TEs) in the parasitic fungus Metarhizium anisopliae can move between species via large mobile genetic elements called 'Starships.' Using HiFi long-read sequencing, researchers found significant genomic differences between two strains, suggesting that these TEs can influence virulence and genome structure. The findings highlight the role of Starships in facilitating horizontal gene transfer among fungi, potentially impacting evolution and adaptation.
Read more →PACBSequencing 101: Software and bioinformatics powering long-read sequencing
The article discusses the transformative role of software and bioinformatics in long-read genome sequencing. It emphasizes how tools like PacBio's SMRT Link streamline the sequencing process, from preparation to analysis. The workflow includes primary, secondary, and tertiary analysis stages, showcasing the importance of accurate data interpretation for meaningful biological insights.
Read more →PACB▲ +7.4%on this news
Powered by PacBio: <br />Selected publications from June 2025
The June 2025 edition of Powered by PacBio highlights significant advancements in RNA sequencing through Iso-Seq and Kinnex kits. Featured studies demonstrate the methods' capabilities in high-confidence isoform quantification and transcriptome annotation across various biological fields. The research showcases the advantages of long-read sequencing over short reads, emphasizing the importance of resolution in understanding complex biological questions.
Read more →PACB▲ +5.7%on this news
Customer success story: <br />How Miami University is using long-read sequencing on the Vega system to train the next generation of scientists
Miami University has successfully integrated the Vega HiFi sequencing system into its genomics program, allowing students to engage in hands-on research. This initiative, led by Dr. Andor Kiss, enables students to conduct complex genomic studies and enhances their educational experience. The Vega system's affordability and ease of use make it ideal for the university's research needs.
Read more →PACBHow HiFi sequencing with the Ampli-Fi protocol can transform newborn screening with dried blood samples
Recent advancements in HiFi sequencing using the Ampli-Fi protocol allow for accurate genome sequencing from dried blood spots, a common sample type in newborn screening. This breakthrough enables the detection of pathogenic variants without the need for parental testing, streamlining workflows. The technology promises to enhance the quality and accessibility of genetic information in newborn screening programs.
Read more →PACBCelebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing
The article celebrates Father's Day by focusing on recent discoveries related to the Y chromosome, emphasizing its complexities and the advancements in HiFi sequencing technology. Researchers from HudsonAlpha Institute and UC Riverside explore the evolutionary significance of sex chromosomes across various species. The findings enhance our understanding of genetic variation and sex determination mechanisms.
Read more →PACBPowered by PacBio:<br /> Selected publications from May 2025
The May 2025 publication roundup showcases the advancements in PacBio HiFi sequencing, highlighting its application in various fields such as infectious disease and antimicrobial resistance. Notable studies include a new method for analyzing HIV-1 reservoirs and insights into antimicrobial resistance plasmid transmissions. These findings emphasize the technology's ability to simplify workflows and enhance data clarity.
Read more →PACB▼ -5.5%on this news
A roadmap to expand PureTarget repeat expansion and carrier panels, enabling high-throughput clinical research solutions
PacBio announced an expansion of its PureTarget portfolio at the ESHG Conference, introducing new repeat expansion and carrier screening panels, along with an automation kit. These innovations aim to enhance high-throughput workflows and improve the detection of complex genetic variations. The updates promise to streamline laboratory operations and offer significant cost savings for researchers.
Read more →PACBHiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms
Recent studies utilizing HiFi sequencing technology have uncovered genomic secrets related to longevity in some of Earth's oldest living organisms, including Jonathan the Aldabra giant tortoise, the Greenland shark, and Goethe's Palm. These findings reveal significant differences in DNA methylation and gene variants associated with aging and resilience. The research not only enhances our understanding of these species but also provides valuable insights for conservation efforts.
Read more →PACBCancer research gains a powerful new tool as Ampli-Fi makes HiFi sequencing possible for FFPE-preserved samples
The Ampli-Fi protocol by PacBio allows HiFi sequencing of FFPE-preserved samples, which were previously incompatible with long-read sequencing. This advancement opens access to valuable cancer research samples, enabling better mutation detection and structural variant analysis. The protocol demonstrates high-quality sequencing capabilities, crucial for understanding cancer behavior and treatment responses.
Read more →PACB▲ +6.2%on this news
Powered by PacBio: <br />Selected publications from April 2025
The April 2025 roundup highlights significant research advancements using PacBio HiFi sequencing. Key studies include the identification of a deep-intronic mutation linked to Joubert syndrome, the generation of comprehensive ape genome references, and improved accuracy in small variant detection for clinical applications. These findings showcase the transformative potential of long-read sequencing across various research fields.
Read more →PACB▲ +6.2%on this newsshared move
Document PacBio Announces First Quarter 2025 Financial Results
PacBio reported disappointing first quarter financial results for 2025, with a GAAP net loss of $426.1 million and a sharp increase in operating expenses. The company did see an improvement in non-GAAP gross margin and record consumables revenue, showcasing strong product demand. However, the organization is under scrutiny due to ongoing investigations related to employment practices. PacBio is pursuing a restructuring plan aimed at reducing costs and focusing on its long-read sequencing technology.
Read more →PACBCustomer success story: <br />How Berry Genomics is transforming complex single-gene disorder assays with HiFi sequencing
Berry Genomics, a leading clinical genomics company in China, has adopted the Vega system to enhance its HiFi sequencing capabilities for complex single-gene disorders. This transition has led to a 3-5% increase in diagnosis rates for conditions like Thalassemia. The company aims to further expand its applications and improve public health outcomes through innovative genomic solutions.
Read more →PACBCelebrating DNA Day and the long-read sequencing tools moving genomics forward
PacBio celebrates DNA Day by highlighting advancements in long-read sequencing technology. Their HiFi sequencing has successfully completed the human genome by filling in previously missing regions. This technology is empowering researchers across various fields, including cancer biology and agriculture, to achieve more accurate and comprehensive genomic insights. The ongoing innovations in sequencing are set to drive future discoveries in genomics.
Read more →PACBCustomer success story: <br />How SPRQ chemistry boosts data output across continents at Signios Biosciences
Signios Biosciences is leveraging SPRQ chemistry to enhance genomic sequencing capabilities. The new chemistry allows for increased data output per SMRT Cell while reducing sample input requirements. This advancement is particularly beneficial for challenging samples, enabling researchers to obtain high-quality genomic data more efficiently. The company anticipates further growth in long-read sequencing applications across various fields.
Read more →PACBDNA extraction tips and best practices for HiFi sequencing
The article discusses best practices for DNA extraction crucial for HiFi sequencing. It highlights the importance of using high-molecular-weight DNA and recommends Nanobind extraction kits for optimal results. Key tips include choosing the right sample type, maintaining sample integrity, and utilizing automation for efficiency. The article serves as a comprehensive guide for researchers in need of effective DNA extraction methods.
Read more →PACB▲ +20.8%on this newsshared move
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q
PacBio announced its preliminary revenue for Q1 2025, reporting $36.9 million, slightly lower than Q1 2024's $38.8 million. The company reiterated its 2025 revenue guidance of $155 million to $170 million while implementing a plan to reduce operating expenses by $45 million to $50 million due to ongoing market uncertainty and NIH funding impacts. Despite the challenges, sales of the Vega system have grown, and consumable revenue reached a record high, indicating strong product demand. A quarterly earnings call is scheduled for May 8, 2025, where more details will be provided.
Read more →PACB▼ -6.3%on this news
Customer success story: The University of Bern takes long-read sequencing to the next level with SPRQ chemistry
The University of Bern's sequencing facility has successfully implemented PacBio's new SPRQ chemistry with the Revio system, enhancing long-read sequencing efficiency. Dr. Pamela Nicholson highlights improved data yield and quality, particularly with challenging samples. The facility's experience suggests that long-read sequencing is becoming more affordable and accessible, paving the way for future genomic research advancements.
Read more →PACBPowered by PacBio:<br />Selected publications from March 2025
The March 2025 edition of PacBio's blog showcases significant advancements in HiFi sequencing across various fields, including clinical genetics, neurology, and agrigenomics. Key studies highlight the resolution of complex genetic regions, improved testing for Congenital Adrenal Hyperplasia, and novel insights into microglia isoforms related to neurodegenerative diseases. These findings underscore the transformative impact of long-read sequencing technology in addressing previously intractable biological questions.
Read more →PACBJim Gibson to join PacBio as Chief Financial Officer
PacBio has announced the appointment of Jim Gibson as its new Chief Financial Officer, effective March 31, 2025. Gibson brings over 30 years of financial experience from notable companies in Silicon Valley, including Tesla and Netflix. He is expected to play a crucial role in advancing PacBio’s financial strategies and achieving its goal of positive cash flows by 2027. Christian Henry, the company’s CEO, expressed optimism regarding Gibson’s ability to contribute to PacBio’s growth and innovation initiatives.
Read more →PACBInspiring the next generation of scientists: How multidisciplinary science powers PacBio technology
PacBio is actively supporting STEM education by sponsoring the Seq It Forward 5K + Fun Run in San Diego, aimed at inspiring young scientists. The event emphasizes the connection between early scientific curiosity and advancements in technology, particularly in HiFi sequencing. By fostering interest in genetics, bioinformatics, and engineering, PacBio aims to equip the next generation with the tools for future discoveries.
Read more →PACB▼ -6.2%on this newsshared move
2024 SMRT Conserve grant winners
PacBio has announced the winners of the 2024 SMRT Conserve grant program, which funds innovative genomic research aimed at conserving endangered species. The selected projects include sequencing efforts for Hawaiian Honeycreepers, Spotted Seatrout, American Crocodiles, Angelsharks, and coastal dolphins in Malaysia. These initiatives leverage advanced sequencing technologies to enhance understanding of species adaptation and support conservation efforts.
Read more →PACBPowered by PacBio: <br />Selected publications from February 2025
The February 2025 edition of Powered by PacBio highlights advancements in HiFi sequencing, showcasing its impact on chromatin assembly, immunology, and gene therapy. Key studies demonstrate improved efficiency in genome assembly and the identification of previously undocumented genetic variations. The findings emphasize the importance of HiFi sequencing in enhancing research accuracy and safety in clinical applications.
Read more →PACB▼ -10.4%on this news
Rare Disease Month: Putting People First
As Rare Disease Month concludes, PacBio reflects on its commitment to rare disease research through the People First campaign. This initiative amplifies the voices of families navigating rare diseases, showcasing their journeys and the impact of genomic technology. The article features inspiring stories of families who have benefited from advancements in long-read sequencing, emphasizing the importance of early diagnosis and intervention.
Read more →PACB▼ -7.3%on this news
How HiFi sequencing is making a difference for rare disease research at Children’s Mercy
Children's Mercy is utilizing PacBio's HiFi sequencing technology to enhance the diagnosis and treatment of pediatric rare diseases. This advanced genomic analysis allows for a more comprehensive understanding of genetic conditions that traditional methods often miss. The research has shown promising improvements in diagnostic rates and aims to shorten the timeline for families seeking answers.
Read more →PACB▲ +8.8%on this news· ran to +36% by day 1
How HiFi sequencing lays the groundwork for accelerating rare disease diagnostics in the clinic
PacBio highlights the advancements in HiFi sequencing during Rare Disease Month, showcasing Radboudumc's efforts to enhance rare disease diagnostics. The technology has demonstrated a 93% success rate in identifying pathogenic variants, potentially reducing the time and cost associated with traditional testing methods. Radboudumc plans to implement HiFi sequencing in routine workflows, aiming to sequence 5,000 genomes.
Read more →PACB▲ +8.8%on this news· ran to +36% by day 1shared move
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
PacBio reported a 33% decline in fourth-quarter revenue for fiscal year 2024 compared to the previous year, totaling $39.2 million. Despite this decrease, the company achieved a GAAP net income of $3.6 million, a turnaround from the $82 million loss in the same quarter last year. The company faced significant operating expenses, totaling $161.9 million, partly due to estimated impairment charges. New product launches, such as the Vega systems, and improved gross margins suggest ongoing innovation amid macroeconomic challenges.
Read more →PACBPowered by PacBio: <br />Selected publications from January 2025
January 2025 marks a significant period for PacBio's HiFi sequencing technology, with multiple studies demonstrating its capabilities in diverse areas such as rare disease diagnostics, plant genomics, and microbial species identification. The featured research highlights advancements in tandem repeat profiling, low-pass sequencing, and multiomic approaches, showcasing the transformative potential of long-read sequencing. These findings emphasize the technology's superiority over traditional short-read methods.
Read more →PACBSequencing 101: Epigenetics
The article discusses the significance of epigenetics and how PacBio's HiFi sequencing technology is revolutionizing the field. It highlights the mechanisms of DNA methylation and chromatin architecture, emphasizing their roles in gene regulation. A recent publication showcases a method that integrates various epigenomic data, enhancing understanding of diseases. Overall, HiFi sequencing is positioned as a transformative tool in biological research.
Read more →PACBPacBio Announces Appointment of Chris Smith to Board of Directors PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down.
PacBio announced the appointment of Chris Smith to its Board of Directors, effective immediately. Smith brings extensive experience in genomics and diagnostics, serving as CEO of NeoGenomics. His addition is expected to enhance PacBio's strategic direction, particularly in clinical genomics. Concurrently, Board Member David Meline has stepped down, after contributing significantly since 2023.
Read more →PACB▼ -8.8%on this news
Publication spotlight: Advancing plant breeding with long-read low-pass sequencing
The article discusses the advancements in plant breeding through low-pass HiFi sequencing, which enhances the accuracy and cost-effectiveness of genomic analyses. Researchers from HudsonAlpha and the University of Georgia demonstrated that HiFi sequencing outperforms traditional short-read methods in identifying genetic variants associated with important traits in peanuts. This technology is positioned as a transformative tool for improving crop resilience and yield.
Read more →PACB▼ -8%on this news· ran to -18% by day 3
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue Commenced shipment of the Vega benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$50
PacBio announced preliminary revenue figures for the fourth quarter and full year of 2024, reporting a decline of 33% in Q4 and 23% for the year. Despite these challenges, the company has launched new products such as the Vega benchtop system and SPRQ chemistry, aiming to increase accessibility to HiFi sequencing. The CEO expressed confidence in market share growth for 2025, supported by progress in the company's clinical market strategy. PacBio's financial position has been bolstered through a recent refinancing deal.
Read more →PACBNew Ampli-Fi ultra-low-input protocol will support HiFi sequencing from as little as 1 ng of DNA
PacBio has introduced the Ampli-Fi protocol, allowing HiFi sequencing from as little as 1 ng of DNA, enhancing the ability to sequence small or challenging genomes. This new workflow improves upon previous low-input protocols by supporting larger genomes and reducing costs. The protocol is expected to be available by the end of Q1 2025.
Read more →PACBPacBio 2024 Wrapped: A year of breakthroughs by the numbers
PacBio's 2024 was marked by significant advancements in genomics, including the launch of the Nanobind PanDNA kit and the Vega system. The company achieved major milestones such as sequencing 10,000 human genomes and enhancing multiomic analysis capabilities. Collaborative efforts and innovative products have positioned PacBio as a leader in genomic research, setting the stage for continued breakthroughs in 2025.
Read more →PACB▲ +10.6%on this news
Powered by PacBio: <br />Selected publications from December 2024
In December 2024, PacBio showcased its technology's impact on genomics through various studies. Highlights include advancements in epigenetic mapping of the human brain, the creation of an Emirati pangenome, and the resolution of complex genetic rearrangements in rare diseases. These findings underscore the potential of HiFi sequencing to enhance research and diagnostics in diverse fields.
Read more →PACBA father’s journey: finding hope through genomics
Casey McPherson's journey as a father to a daughter with a rare neurodevelopmental disease emphasizes the hope brought by genomic advancements. After a long diagnostic journey, Casey discovered that his daughter Rose has a rare genetic mutation. Utilizing PacBio HiFi sequencing, he aims to develop targeted treatments, transforming his family's challenges into a mission to help others facing similar struggles.
Read more →PACB▼ -9.9%on this news
Garvan Institute researchers demonstrate that saliva samples are viable for long-read sequencing
Researchers at the Garvan Institute have shown that saliva samples are a viable source for high-quality long-read sequencing. Using Oragene™ and Nanobind® kits, they successfully extracted high-molecular-weight DNA from saliva collected years ago. The study indicates that saliva can serve as an alternative to blood samples, enhancing the feasibility of genomic research.
Read more →PACBPowered by PacBio: <br>Selected publications from November 2024
PacBio highlights recent publications showcasing the advancements in HiFi sequencing. Researchers are utilizing this technology to explore hereditary hearing impairment, single-cell epigenetics, and rare diseases. Notable studies include a national initiative in Sweden for digital karyotyping and a comprehensive analysis of STRC variants in hearing impairment. These findings underscore the significant impact of PacBio's sequencing technology in genomics.
Read more →PACBLighting a SPRQ: How new Revio chemistry fuels innovative research
PacBio has introduced SPRQ chemistry for its Revio system, enhancing HiFi sequencing technology. This innovation promises improved efficiency, affordability, and reduced DNA input requirements, allowing researchers to explore complex genomes and multiomic insights. The new chemistry also supports significant advancements in neonatal research and population genetics studies.
Read more →PACBGaining deeper insight with targeted sequencing
PacBio has launched the Vega system and SPRQ chemistry, enhancing targeted sequencing capabilities. This approach allows researchers to focus on specific genomic regions, improving efficiency and reducing costs. Targeted sequencing is crucial for understanding genetic contributions to diseases and is particularly valuable in fields like cancer and pharmacogenomics. PacBio's technology supports comprehensive insights into complex genomic areas.
Read more →PACB▼ -6.3%on this news· ran to -19% by day 1
Introducing the Vega system – HiFi sequencing within reach
PacBio has launched the Vega system, a benchtop HiFi long-read sequencing platform that aims to make advanced sequencing technology accessible to all laboratories. The Vega system offers high precision and reliability similar to the Revio system, with a focus on democratizing long-read sequencing. Priced at $169,000, it supports various applications, including targeted sequencing and full-length RNA sequencing.
Read more →PACB▼ -7.5%on this news
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
PacBio has announced a private exchange transaction involving $459 million of its Convertible Senior Notes due 2028. As part of this, the company will issue $200 million in new notes due 2029, provide approximately 20.5 million shares of common stock, and make a cash payment of $50 million. This restructuring is intended to extend and reduce their long-term debt while balancing the potential dilution for shareholders. The transaction is expected to close around November 21, 2024, pending customary closing conditions.
Read more →PACB▼ -7.5%on this news
PacBio Announces Third Quarter 2024 Financial Results
PacBio reported its financial results for the third quarter of 2024, showing a gross profit of $10.0 million and a net loss of $60.7 million. The company's operating expenses have decreased significantly from the previous year, reflecting ongoing cost-management efforts. Despite a continued challenging macroeconomic environment for capital purchases, executive comments suggest optimism about a potential path to growth in 2025, bolstered by increased adoption of its sequencing platforms. The company also emphasizes its goal to achieve cash flow positivity by the end of 2026.
Read more →PACBPowered by PacBio: <br>Selected publications from October 2024
PacBio's HiFi sequencing technology is highlighted in recent publications from October 2024, showcasing its significant impact on genomic research. Key studies demonstrate improved diagnostic yields for pediatric sensorineural hearing loss and the creation of a comprehensive tandem repeat catalog. Additionally, a proteogenomic atlas of the human neural retina reveals critical insights into inherited retinal diseases. These advancements underscore PacBio's role in facilitating groundbreaking discoveries in genomics.
Read more →PACBWhat are genomic variants and why do they matter?
The article discusses the significance of genomic variants in understanding genetic diversity and disease susceptibility. It highlights various types of variants, including single nucleotide variants, indels, structural variants, and copy number variants. PacBio's HiFi sequencing technology is emphasized for its accuracy in detecting these variants, which is vital for health research, agriculture, and environmental sustainability.
Read more →PACB▼ -7.8%on this news
The truth about sequencing accuracy and how PacBio leads the way
PacBio is leading advancements in DNA sequencing accuracy with its HiFi and SBB technologies. Recent studies highlight the effectiveness of PacBio's sequencing in cancer research, neuroscience, and microbiology, showcasing lower error rates and improved diagnostic yields. These innovations position PacBio at the forefront of the 'era of accuracy' in genomic research.
Read more →PACBChild Health Day 2024 – the power of HiFi sequencing in rare disease research
The article highlights the significance of Child Health Day and the role of HiFi sequencing in addressing undiagnosed rare diseases. It discusses the challenges families face in obtaining diagnoses and how long-read sequencing can reveal critical genetic information. Institutions like Radboud University and Children’s Mercy Kansas City are utilizing this technology to improve diagnostic rates and provide hope for affected families.
Read more →PACBPowered by PacBio: <br>Selected publications from September 2024
PacBio's HiFi sequencing technology continues to lead in accuracy, facilitating significant advancements in various biological fields. Recent publications highlight its application in understanding disease-associated transcript isoforms, improving germline testing for rare diseases, and enhancing crop breeding strategies. These studies demonstrate the transformative potential of PacBio technology in genomic research.
Read more →PACB▼ -10.5%on this news· ran to -22% by day 3
RNA sequencing with Kinnex kits transforms University of Southampton rare disease research
Professor Diana Baralle from the University of Southampton discusses the transformative impact of PacBio RNA sequencing with Kinnex kits on rare disease research. This technology enhances the understanding of RNA splicing and variant significance, aiding in clinical diagnostics. An international working group is being formed to address barriers to adoption and integrate RNA sequencing into clinical settings, with the potential for personalized therapies.
Read more →PACB▲ +7.1%on this news
2024 Microbial Genomics SMRT Grant Awardees
The 2024 Microbial Genomics SMRT Grant winners have been announced, showcasing innovative research proposals in the field of microbiome and metagenomics. Notable winners include Amanda Shelton for her project on microbial diversity in hot springs and Meagan Dewar for studying Antarctic wildlife microbiota. The grants will support groundbreaking research using HiFi sequencing technology.
Read more →PACB▲ +6.1%on this news· ran to +32% by day 3
HiFi sequencing delivers confidence for cell and gene therapy research
PacBio's HiFi sequencing technology combines short- and long-read capabilities, providing 99.9% accuracy essential for cell and gene therapy research. It significantly enhances the design and evaluation of AAV vectors, which are crucial for successful gene therapies. Additionally, HiFi sequencing aids in detecting off-target effects in CRISPR-Cas9 gene editing, ensuring safety and efficacy in therapeutic applications.
Read more →PACBPowered by PacBio: <br>Selected publications from August 2024</br>
PacBio highlights significant advancements in genomic research through its HiFi sequencing technology in August 2024. Key publications showcase the technology's superiority in detecting rare mutations, analyzing allele-specific expression, and understanding genetic inheritance. The studies emphasize the benefits of PacBio's methods over traditional sequencing technologies, paving the way for groundbreaking discoveries in genetics and evolutionary biology.
Read more →PACB▼ -6.8%on this news
Announcing the winners of the 2024 STAR grant for gene and cell therapy research
PacBio has announced the winners of the 2024 STAR grant aimed at advancing gene and cell therapy research. The grant provides selected researchers with free HiFi sequencing and travel stipends to present their findings. Notable winners include Ramiro Perrotta, Dawn Chen, and Yannick Brüggemann, who proposed innovative projects utilizing advanced sequencing technologies.
Read more →PACB▲ +25.2%on this news
Leveraging genomic surveillance in wastewater to protect public health
PacBio's Onso short-read sequencing system is enhancing wastewater surveillance to monitor public health threats, including antimicrobial resistance. A recent collaboration with Zymo Research demonstrated the system's superior ability to detect resistance genes compared to traditional methods. This advancement is crucial for informing public health decisions and optimizing management strategies against emerging health threats.
Read more →PACB▲ +9.2%on this news
Breakthrough research: </br>Characterizing degenerative repeat expansion disorders with PacBio PureTarget panel
PacBio has launched the PureTarget repeat expansion panel, enhancing the study of tandem repeat disorders linked to neurological diseases. This panel utilizes HiFi sequencing technology to accurately target previously inaccessible genomic regions. Research utilizing this panel is advancing understanding of conditions such as ALS and Fuchs Endothelial Corneal Dystrophy, paving the way for potential new treatments.
Read more →PACBDocument PacBio Announces Second Quarter 2024 Financial Results
PacBio reported a significant decline in financial performance for Q2 2024, with revenues dropping to $36.0 million from $47.6 million in the previous year. Instrument revenue particularly suffered, falling from $29.9 million to $14.7 million. Increased operating expenses, primarily due to a goodwill impairment charge totaling $93.2 million, led to a net loss of $173.3 million. Despite these challenges, the company experienced growth in consumables revenue and announced positive partnerships to enhance its offerings in precision medicine.
Read more →PACB▼ -6.8%on this news· ran to -22% by day 3
Powered by PacBio: <br>Selected publications from July 2024</br>
PacBio's HiFi sequencing technology continues to lead in genomic research, as highlighted by recent publications from July 2024. These studies cover advancements in bioinformatics, targeted sequencing, and metagenomics, showcasing the technology's ability to resolve complex genetic architectures and improve mutation detection. The findings emphasize PacBio's role in pushing the boundaries of genomic exploration.
Read more →PACBUnderstanding Parkinson’s disease and its innovative therapies
The article discusses innovative therapies for Parkinson's Disease (PD), highlighting community-driven initiatives and scientific advancements. Notably, antisense oligonucleotides (ASOs) targeting the alpha-synuclein protein are being researched, with promising results in early trials. The use of PacBio's Iso-Seq method has revealed novel transcript variants that could improve treatment strategies.
Read more →PACB▼ -15.4%on this news
Sequencing 101: Comparing long-read sequencing technologies
The article compares long-read sequencing technologies, focusing on HiFi and nanopore sequencing. HiFi sequencing is highlighted for its high accuracy and ability to detect complex genomic variations, making it suitable for applications like rare disease research. In contrast, nanopore sequencing is noted for its rapid data generation, beneficial during disease outbreaks. The choice of technology depends on factors such as accuracy, application fit, and cost.
Read more →PACBPowered by PacBio: </br>Selected publications from June 2024
PacBio highlights recent scientific publications showcasing its HiFi sequencing technology's advantages in genomics. Key findings include superior performance in single-cell RNA-seq analyses, insights into segment duplications, and advancements in gene regulation and metagenomics. The technology's versatility is emphasized, making it a preferred choice for researchers across various biological domains.
Read more →PACBGoing beyond the “needle in a haystack” with Onso short-read sequencing
PacBio has launched summer promotions for its Onso short-read sequencing system, which boasts Q40+ accuracy, significantly improving research precision. The system's innovative sequencing by binding (SBB) chemistry enhances sensitivity and specificity, making it ideal for applications in oncology, public health, and human genetics. Collaborations have shown Onso's superior performance in detecting microbial diversity and low-frequency variants.
Read more →PACBWinning human RNA SMRT Grant proposals announced
The 2024 human RNA SMRT Grant winners have been announced, showcasing innovative proposals in genomics research. Notable winners include Christopher Vollmers for tissue-level annotation of the human genome and Douglas Brownfield for studying FGFR2 isoform expression in pulmonary emphysema. These projects highlight the potential of long-read sequencing to enhance understanding of various diseases.
Read more →PACB▼ -6.6%on this news· ran to -17% by day 3
Sequencing 101: Metagenome-assembled genomes
The article discusses the significance of metagenome-assembled genomes (MAGs) in understanding microbial diversity, particularly for non-culturable microorganisms. It highlights advancements in sequencing technology, especially PacBio's HiFi sequencing, which enables the creation of high-quality MAGs. The article also outlines the process of generating MAGs and their implications for various fields, including human health and environmental science.
Read more →PACBPowered by PacBio: Selected publications from May 2024
PacBio highlights recent scientific publications from May 2024, showcasing the effectiveness of its HiFi sequencing technology in addressing rare diseases and genetic research. Key studies demonstrate the identification of disease-causing variants, the discovery of new genetic mutations linked to thyrotropin resistance, and advancements in single-cell RNA sequencing. These findings underscore PacBio's role in facilitating breakthroughs in genomics.
Read more →PACB▲ +6.6%on this news
Customer success story: </br>Maryland Genomics shines by tackling tough samples with HiFi sequencing
Maryland Genomics, part of the Institute for Genome Sciences, specializes in high-throughput genomic analysis, utilizing the Revio system for sequencing diverse organisms. Their expert team collaborates globally on various projects, offering tailored sequencing solutions. The Revio system enhances data yield and quality, making it easier to work with challenging samples.
Read more →PACBLong-read sequencing myths: debunked. </br>Part 6 — cell & gene therapy
The article discusses the role of HiFi long-read sequencing in enhancing cell and gene therapy research, particularly with AAV vectors. It debunks common myths about the technology, emphasizing its cost-effectiveness and accuracy in product design and safety assessments. The FDA's recent approvals of AAV-based therapies highlight the importance of this sequencing method in advancing gene therapy applications.
Read more →PACBLong-read sequencing myths: debunked. </br>Part 5 — microbiology
PacBio's HiFi sequencing technology is revolutionizing microbial genomics by providing high-resolution insights into microbial communities. This article debunks common myths surrounding the technology, emphasizing its accuracy, cost-effectiveness, and scalability. The Revio system enhances throughput, making it easier to conduct comprehensive microbial studies. Overall, PacBio is setting new standards in metagenomics and microbiome research.
Read more →PACB▲ +15.5%on this newsshared move
New hope for neurodegenerative diseases
PacBio's PureTarget technology is enhancing dementia research by enabling precise targeting of genetic mutations linked to neurodegenerative diseases. Dr. Claire Clelland's team is focusing on the C9orf72 gene, which is associated with ALS and frontotemporal dementia. The new no-amplification sequencing method allows for better quantification of repeat expansions, facilitating the development of CRISPR therapies. This advancement promises to improve outcomes in gene therapy for neurological conditions.
Read more →PACBDocument PacBio Announces First Quarter 2024 Financial Results
PacBio reported its financial results for Q1 2024, showing a revenue of $38.8 million, slightly down from $38.9 million in the previous year. The company achieved a gross profit of $11.3 million, marking a 16% increase year-over-year. However, PacBio's net loss improved to $78.2 million, but the overall performance reflects challenges in instrument sales and high operating expenses. The firm remains focused on enhancing its commercial execution and product offerings.
Read more →PACBPowered by PacBio: Selected publications from April 2024
The latest edition of the Powered by PacBio blog highlights significant scientific publications from April 2024 that demonstrate the capabilities of PacBio's HiFi sequencing technology. These studies cover a range of topics, including the sequencing of sugarcane, isoform diversity in great apes, and splicing patterns in mouse and human brains. The advancements in PacBio technology are facilitating groundbreaking discoveries in genomics.
Read more →PACBLong-read sequencing myths: debunked. <br>Part 4 — plant and animal</br>
The article debunks common myths surrounding PacBio's long-read sequencing technology in plant and animal genomics. It emphasizes the advantages of HiFi reads, including their accuracy and cost-effectiveness with the Revio system. The piece highlights the technology's ability to generate high-quality genome assemblies and its applications in studying complex genomes. Additionally, it addresses misconceptions about DNA requirements and library preparation.
Read more →PACBKinnex in three acts: full-length RNA sequencing for human disease research
PacBio's Kinnex kits revolutionize RNA sequencing by enabling high-throughput, full-length isoform sequencing. Researchers are utilizing these kits to uncover critical insights into rare diseases, quantify RNA isoforms, and study isoform switching in cardiovascular tissues. The Kinnex technology promises to enhance the understanding of gene expression and its implications in human health.
Read more →PACBLong-read sequencing myths: debunked. <br>Part 3 — cancer genomics</br>
The article discusses the advancements in cancer genomics facilitated by PacBio's HiFi long-read sequencing technology. It debunks common myths surrounding sequencing methods, emphasizing the superiority of long reads over short reads for detecting genomic variations and improving accuracy in cancer research. The article highlights the benefits of PacBio's Kinnex kits and the Revio system in providing comprehensive insights into tumor biology.
Read more →PACB▼ -50.6%on this newsshared move
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for
PacBio announced preliminary revenue results for Q1 2024, which fell short of expectations due to customer delays in instrument purchases and reduced consumable shipments. Despite these challenges, the company remains optimistic about its Revio instruments and expects improvements in revenue as sales cycles stabilize. PacBio is also planning to reduce annualized operating expenses by $50-$75 million to adapt to the current financial outlook. The revised revenue guidance for 2024 is set between $170 million to $200 million, a decrease from prior expectations.
Read more →PACBLong-read sequencing myths: debunked. <br>Part 2 — human genomics</br>
The article debunks common myths surrounding HiFi long-read sequencing in human genomics. It highlights the technology's high accuracy, affordability, and ability to provide comprehensive genomic insights. The Revio system is emphasized for its efficiency and scalability, making long-read sequencing accessible for various research applications. The piece aims to reset expectations about the capabilities of long-read sequencing.
Read more →PACBPowered by PacBio: Selected publications from March 2024
The article discusses recent publications from March 2024 that utilize PacBio's HiFi sequencing technology across various biological domains. Key studies include advancements in fusion detection, immunology, primate genome analysis, and the interaction of saliva with wine. These findings emphasize the versatility and power of PacBio sequencing in enabling significant scientific discoveries.
Read more →PACBLong-read sequencing myths: debunked. <br>Part 1- HiFi sequencing</br>
The article debunks common myths surrounding PacBio's HiFi long-read sequencing technology. It highlights the significant advancements in accuracy, cost-effectiveness, and scalability of HiFi sequencing compared to traditional methods. The article emphasizes that HiFi sequencing is no longer a niche technology but a versatile tool for comprehensive genomic research. It invites readers to stay tuned for further myth-busting in the series.
Read more →PACBLeading the way into the future: HiFi whole genomes as a replacement for exome and short-read genome sequencing
The article discusses the advantages of HiFi whole-genome sequencing over traditional exome and short-read sequencing methods. It highlights how organizations like Children's Mercy and Bioscientia are utilizing HiFi sequencing to achieve faster and more accurate genetic diagnoses. The technology captures a broader range of genetic variants, addressing limitations of previous methods and paving the way for future advancements in genomics.
Read more →PACB▲ +5.7%on this news
TGen sees big developments coming for cancer liquid biopsy research thanks to ultra-accurate PacBio short reads
TGen is advancing liquid biopsy assays for early cancer detection using PacBio's Onso short-read sequencing technology. The Onso system's high accuracy enhances the ability to differentiate between healthy and cancerous samples, significantly improving predictive capabilities. Upcoming data from TGen will showcase the effectiveness of these assays at the AACR annual meeting.
Read more →PACBPowered by PacBio: Selected publications from February 2024
PacBio highlights recent publications demonstrating the effectiveness of its HiFi sequencing technology in various biological domains. Key studies include advancements in cancer transcriptomics, rare diseases, neurobiology, and agrigenomics. These findings underline the technology's role in unraveling complex biological questions and enhancing genomic research.
Read more →PACBProgress report: HiFi sequencing enables Care4Rare Consortium to advance rare disease research
The Care4Rare Canada Consortium, in collaboration with PacBio, has made significant progress in rare disease research using HiFi sequencing. Dr. Kym Boycott highlighted that this technology has successfully identified genetic causes in previously unsolved cases. The initiative aims to enhance diagnostic pathways and expand access to genomic testing for families affected by rare diseases.
Read more →PACBWatch: Kinnex kits enable full-length 16S and RNA sequencing at scale
The article discusses the launch of Kinnex kits by PacBio, which enable high-throughput full-length 16S and RNA sequencing. These kits are designed to improve the accuracy and accessibility of genomic research, particularly in microbiome studies and gene annotation. Experts highlight the advantages of Kinnex, including increased throughput and cost-effectiveness compared to traditional sequencing methods.
Read more →PACB▼ -7.8%on this newsshared move
Rare disease research. Can HiFi sequencing help shorten the journey to answers?
Researchers at Radboud University Medical Center are exploring HiFi sequencing to expedite the diagnosis of rare genetic diseases. This innovative approach aims to deliver accurate genetic diagnoses in under a week through a simple blood test. Preliminary results show that HiFi sequencing can identify a high percentage of genetic variants, potentially replacing existing diagnostic workflows. The Nijmegen Revio-500 Study is a significant step in advancing diagnostic capabilities for rare diseases.
Read more →PACBDocument PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
PacBio has announced its financial results for Q4 and FY 2023, highlighting a significant revenue increase of 113% year-over-year to $58.4 million in Q4. Despite this growth, the company reported a net loss of $82 million for the same quarter, though it was an improvement over the previous year's loss. Key developments included the launch of the HiFi Solves consortium and advancements in sequencing technology with the release of new software and RNA kits. Overall, PacBio continues to innovate while navigating challenges related to operating expenses and inventory management.
Read more →PACB▼ -9.4%on this newsshared move
Powered by PacBio: Selected publications from January 2024
The article highlights recent scientific publications in January 2024 that utilize PacBio's HiFi sequencing technology. These studies demonstrate advancements in metagenomics, agrigenomics, and cancer research, showcasing the technology's ability to unravel complex biological data. Notable tools like metaMDBG and TRGT are emphasized for their contributions to genomic analysis.
Read more →PACB2023 gene therapy research STAR Grant winners announced
PacBio has announced the winners of its inaugural STAR Grant program, aimed at supporting emerging researchers in genomics. The selected proposals focus on various innovative gene therapy approaches, including treatments for Rett syndrome and Duchenne muscular dystrophy. The grants will provide funding for sequencing services and travel stipends for the researchers to present their work.
Read more →PACBWinning proposals for 2023 PacBio grants announced
PacBio has announced the winners of its 2023 grant program, which provides free sequencing services to innovative research proposals. The winning projects include studies on climate-resilient bioenergy feedstocks and precision medicine for inherited retinal dystrophies. These initiatives aim to leverage PacBio's advanced sequencing technologies to address significant scientific challenges.
Read more →PACBHighly accurate sequencing enables the detection of microsatellite instability associated with cancer
The PacBio Onso short-read sequencing system demonstrates high accuracy in detecting microsatellite instability (MSI) associated with various cancers. Preliminary results from the DOvEEgene project at McGill University indicate that Onso outperforms traditional sequencing methods. This advancement could significantly impact early cancer detection and treatment strategies, particularly for ovarian and endometrial cancers.
Read more →PACB▼ -18.5%on this newsshared move
Document PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively Ships a record number of PacBio sequencers in 2023, including 173 Revio TM systems, and announces recor
PacBio has reported a record preliminary revenue of $58.4 million for the fourth quarter of 2023, representing a significant year-over-year growth of 113%. Full-year revenue also surged by 56%, reaching $200.5 million, driven by the successful launch and demand for its Revio and Onso sequencing systems. The company has pointed to increasing interest in long-read sequencing technologies and successful collaborations to further expand its market reach. However, PacBio's future performance remains uncertain due to inherent risks in product development and market competition.
Read more →PACBMastering AAV vector design: Best practices for gene therapy product characterization using HiFi sequencing
The article discusses the recent FDA approvals of several AAV-based gene therapies, highlighting the significance of advancements in vector design and characterization. It emphasizes the role of HiFi sequencing in improving safety and efficacy by identifying impurities in AAV products. The piece also notes the challenges faced during clinical development, including safety concerns and the complexity of gene therapy design.
Read more →PACBOur favorite publications of 2023
The article highlights key publications in genomics from 2023, showcasing significant advancements in various fields such as cancer biology and human genomics. It emphasizes innovative methodologies and foundational breakthroughs, including the complete sequencing of the human Y chromosome and multiomics research. The piece reflects on the achievements of PacBio and anticipates further advancements in 2024.
Read more →PACBHigh-quality genomes for a biodiverse Christmas
The Darwin Tree of Life Project has successfully assembled high-quality genomes of various holiday-associated species, including birds and plants, using accurate HiFi sequencing. This initiative enhances the understanding of the molecular mechanisms behind Christmas. The project highlights contributions from numerous scientists and reflects on the achievements made in genomic research over the past year.
Read more →PACB▲ +10.6%on this newsshared move
Sequencing 101: Structural variation
The article discusses the significance of structural variation (SV) in genetics and genomics, highlighting its role in understanding genetic diversity and human diseases. It explains various types of SVs, such as insertions, deletions, and duplications, and their implications for phenotypes and health. The advent of high-throughput sequencing technologies, particularly PacBio HiFi sequencing, is emphasized as a game changer for SV research.
Read more →PACBKinnex launch promises to revolutionize RNA research
PacBio has launched Kinnex full-length RNA kits, which dramatically enhance RNA sequencing throughput, allowing for 15 million reads per SMRT Cell on the Sequel II and 40 million on the Revio system. This innovation addresses previous limitations in RNA sequencing, enabling large-scale studies and providing a clearer view of isoform diversity. The Kinnex kits promise to revolutionize RNA research by facilitating more comprehensive and accurate analyses.
Read more →PACBPowered by PacBio: Selected publications for November 2023
The article discusses recent publications from November 2023 that utilize PacBio HiFi sequencing technology in various biological fields. It highlights significant studies in immunology, medical genetics, and human embryonic development, showcasing the technology's capability to resolve complex genetic structures and improve disease detection. The article emphasizes the growing accessibility of PacBio sequencing for research teams.
Read more →PACBA HiFi movement: Transcript isoform resolved RNA sequencing
Recent advancements in HiFi long-read sequencing, particularly through PacBio's Iso-Seq method, are transforming our understanding of RNA transcript isoforms. Studies have identified numerous unannotated isoforms in early human development and highlighted the impact of alternative splicing on protein diversity. The introduction of the Revio system and Kinnex RNA sequencing kits promises to significantly enhance throughput and efficiency in RNA sequencing projects.
Read more →PACBSequencing 101: Tandem repeats
The article discusses the significance of tandem repeats in genetics, highlighting their structure, types, and impact on genetic diseases. It emphasizes the advancements in DNA sequencing technologies, particularly PacBio's HiFi sequencing, which enable more effective study of these repetitive sequences. The article also introduces specialized software tools that enhance the analysis of tandem repeats.
Read more →PACB▲ +8.2%on this news· ran to +19% by day 3
Empowering the pharmacogenomics research community with long-read sequencing
The article discusses the advancements in pharmacogenomics (PGx) through long-read sequencing, particularly using PacBio technology in collaboration with Twist Bioscience. The new PGx panel allows for more accurate drug response predictions by focusing on specific genes. Additionally, a grant is available to support PGx research targeting under-represented populations, enhancing accessibility and diversity in genomic studies.
Read more →PACBCapturing human genomic diversity
Researchers have developed a new Arab pangenome reference from 43 individuals, enhancing the understanding of genetic diversity within Arab populations. Utilizing advanced long-read sequencing technologies, the study reveals significant genetic variants unique to this demographic, which have been historically underrepresented in global genomic projects. This resource is expected to facilitate future research in genetics and disease associations.
Read more →PACBPowered by PacBio: Selected publications for October 2023
PacBio's HiFi sequencing technology is highlighted in recent publications for its role in advancing research in diverse fields such as rare diseases, neurobiology, and epigenetics. Notable studies include the discovery of novel transcripts related to Batten disease and insights into alternative splicing during brain development. The technology's versatility continues to facilitate significant scientific breakthroughs.
Read more →PACBRevio metagenomics + Kinnex 16S data release demonstrate futuristic microbiome capabilities
PacBio has launched the Revio system and Kinnex 16S rRNA kit, enhancing microbiome research through improved sequencing capabilities. The Revio system offers a 15x increase in throughput, while the Kinnex kit allows for a substantial boost in 16S taxonomic data generation. These advancements are supported by new datasets developed in collaboration with Zymo Research, aimed at facilitating metagenomic studies.
Read more →PACBDocument PacBio Announces Third Quarter 2023 Financial Results
PacBio (NASDAQ: PACB) reported its third quarter 2023 financial results, revealing a 72% year-over-year revenue increase, totaling $55.7 million. Instrument revenue surged significantly, thanks to the recognition of sales from 52 Revio sequencing systems. However, the gross profit margin declined from the previous year's quarter, reflecting increased operating expenses which rose to $100.4 million. Despite a net loss reduction compared to the previous year, higher costs remain a concern.
Read more →PACBPowered by PacBio: Selected publications for September 2023
PacBio's HiFi sequencing technology is highlighted in recent publications for its significant contributions to various research fields, including immune response, genetic disease detection, agrigenomics, and Alzheimer's research. Studies demonstrate the technology's ability to reveal novel insights and complex transcriptome landscapes. The accessibility of PacBio sequencing is emphasized, encouraging researchers to utilize these advancements.
Read more →PACBDocument PacBio Announces Appointment of David Meline to Board of Directors Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board
PacBio has appointed David Meline to its Board of Directors, effective October 13, 2023. Meline, who previously served as CFO for Moderna, Amgen, and 3M, brings a wealth of experience in leading organizations through growth phases. His deep understanding of healthcare and genomics is anticipated to enhance PacBio's strategic direction. With a strong educational background and seated positions on other boards, Meline is poised to contribute significantly to PacBio's objectives in advancing genomic technologies.
Read more →PACBInto the multiome: Four high-quality ‘omes from a single Revio SMRT Cell run
Researchers have developed a new multiomic approach that generates four high-quality 'omes from a single Revio SMRT Cell run. This method combines advanced sequencing technology and machine learning to provide insights into complex biological interactions. The approach has shown promise in understanding unexplained diseases and has potential applications across various fields. The findings will be presented at the upcoming ASHG conference.
Read more →PACBHiFi sequencing enables researchers to complete and analyze the Y chromosome
Recent studies utilizing PacBio HiFi long-read sequencing have successfully completed the sequencing of the human Y chromosome, a significant milestone in genomics. The Telomere-to-Telomere Consortium and the Human Genome Structural Variation Consortium published their findings, revealing new insights into male sexual development and fertility. These advancements are expected to enhance research in various fields, including cancer and evolution.
Read more →PACBPowered by PacBio: Selected publications for August 2023
In August 2023, PacBio users published significant research utilizing PacBio sequencing methods. Key highlights include the completion of the human Y chromosome and advancements in Mendelian genetics. The research showcases the potential of long-read sequencing to enhance genetic disorder diagnostics and improve our understanding of human genomics and rare diseases.
Read more →PACB▲ +5.1%on this news
Iso-Seq method outperforms other long-read methods in benchmarking consortium study
The LRGASP consortium's assessment highlights the superior performance of the PacBio Iso-Seq method for detecting and quantifying long and rare transcript isoforms compared to other long-read RNA sequencing technologies. The study demonstrated that PacBio consistently identified more genes and provided higher abundance resolution for isoform quantification. Additionally, the validation of novel isoforms showed a 100% success rate, underscoring the method's reliability.
Read more →PACBWhy SBB could be a game-changer for liquid biopsy research
PacBio's new sequencing technology, SBB, is set to transform liquid biopsy research by improving the detection of circulating tumor DNA (ctDNA). The Onso system offers unprecedented accuracy, enabling researchers to identify rare cancer variants more effectively. This advancement addresses critical challenges in liquid biopsy assays and enhances the potential for non-invasive cancer diagnostics.
Read more →PACBFaster and more affordable sequencing with the HiFi microbial high-throughput workflow
PacBio has launched a new high-throughput workflow that significantly improves the efficiency and affordability of microbial genome sequencing. This innovative approach allows researchers to process up to 96 samples at a time for less than $1.00 each, with a processing time of just three minutes. The new protocols and assembly algorithms enhance the overall accuracy and quality of genomic data, making it easier for microbiologists to conduct comprehensive studies.
Read more →PACBSequencing 101: SBB sequencing
PacBio has introduced Sequencing by Binding (SBB) technology, enhancing short-read sequencing accuracy to Q40+ with an error rate of 1 in 10,000 bases. This breakthrough addresses limitations of traditional short-read sequencing by separating binding and incorporation steps, thus minimizing errors and molecular scarring. SBB technology promises to revolutionize genomic research and applications, enabling more sensitive detection of rare variants.
Read more →PACB▼ -6.1%on this news
Document PacBio Announces Second Quarter 2023 Financial Results Menlo Park, Calif.
PacBio reported its financial results for the second quarter of 2023, revealing a 34% increase in revenue to $47.6 million. The company recognized sales of 47 sequencing systems, including 45 Revio systems, while instrument revenue saw a significant increase. Despite revenue gains, the gross profit margin fell to 33%, and the company made a net loss of $69.8 million. PacBio is progressing with its Onso platform shipment and plans to acquire Apton Biosystems to enhance its sequencing technology.
Read more →PACBWatch: A method for chromosome-level phasing of HiFi assemblies
The article discusses advancements in chromosome-level phasing using PacBio's HiFi sequencing technology. Tools like DipAsm and pstools are highlighted for their ability to produce accurate haplotype-resolved assemblies quickly. The Human Pangenome Reference Consortium supports these methods, showcasing their effectiveness in generating high-quality genomic data. The growing community around PacBio tools indicates a promising future for genomic research.
Read more →PACBA HiFi movement: Isoform-resolved cell atlases
The article discusses the advancements in cellular cartography through isoform-resolved cell atlases, particularly using PacBio's Iso-Seq method. Recent publications highlight significant findings in various fields, including cancer research and malaria transmission. The ENCODE project has expanded its RNA data collection, revealing diverse transcript structures. These developments promise to enhance our understanding of cellular functions and disease mechanisms.
Read more →PACBBeyond borders: The 2023 Discoveries Roadshow ignites curiosity worldwide
The 2023 PacBio Discoveries Roadshow successfully engaged over 1,800 scientists across 33 cities in the Americas and Europe. The event highlighted advancements in long-read sequencing technology, particularly the Revio system, and provided attendees with exclusive insights into new data. Participants appreciated the networking opportunities and the diverse range of presentations that spanned various research topics.
Read more →PACBThe next era of plant + animal genomics has begun
The Revio long-read sequencing system is revolutionizing plant and animal genomics by providing researchers with the ability to generate large volumes of high-quality genomic data quickly and cost-effectively. With its advanced capabilities, the Revio system allows for significant advancements in genomic research, enabling the sequencing of complex genomes and enhancing the discovery of structural variants. This technology is expected to empower more researchers to tackle ambitious genomic questions.
Read more →PACBPacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030
PacBio announced a private exchange agreement to issue $441 million in 1.375% Convertible Senior Notes due 2030, in place of existing 1.50% Convertible Senior Notes due 2028. This exchange is expected to close by June 30, 2023, and is intended to strengthen the company's financial position while providing greater flexibility for future growth. The new notes will pay interest semi-annually and provide optional cash or stock settlement upon conversion.
Read more →PACBDocument PacBio Announces Record Revenue in First Quarter 2023 Menlo Park, Calif.
PacBio reported record revenue of $38.9 million for the first quarter of 2023, marking a 17% increase from the previous year. The company shipped 38 sequencing systems and experienced strong customer demand, particularly for the newly launched Revio system. However, there was a significant decrease in gross profit and an increase in operating expenses, resulting in a higher net loss compared to the same period last year. Despite these challenges, PacBio maintains a strong cash position of $874.9 million as of March 31, 2023.
Read more →PACBPacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results Menlo Park, Calif. –
PacBio reported a significant decline in financial performance for the fourth quarter and fiscal year 2022. The company experienced a gross profit drop of 69% for Q4 2022 compared to Q4 2021, alongside a rising net loss which jumped to $84.4 million from $69.3 million year-over-year. Operating expenses also increased notably, affecting overall profitability. Despite these challenges, the company noted strong demand for its Revio product and ongoing customer enthusiasm for new offerings.
Read more →PACBPacific Biosciences of California, Inc. Announces Pricing of Upsized Public Offering of Common Stock
Pacific Biosciences of California, Inc. announced the pricing of its upsized public offering of 17.5 million shares at $10.00 each. The company expects to raise around $175.0 million from this offering, with potential additional funds from underwriters' options. The proceeds will be utilized for research and development, commercial expansion, and general corporate purposes, including potential investments in complementary businesses or technologies. The offering is anticipated to close by January 27, 2023, subject to standard closing conditions.
Read more →PACB▲ +12.6%on this news· ran to +30% by day 3
PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022 PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches
PacBio announced record orders for 76 Revio systems in Q4 2022, marking a significant milestone for the company. The Revio system allows researchers to perform large-scale genomic studies, while the Onso system received positive feedback from beta testing partners. Despite a decline in preliminary instrument revenue compared to the previous year, the company remains optimistic about its future as it prepares to launch commercial sales of both systems. Preliminary financial results are set to be finalized in February 2023.
Read more →PACBPacBio Announces Third Quarter 2022 Financial Results Menlo Park, Calif. –
PacBio Announces Third Quarter 2022 Financial Results Menlo Park, Calif. November 7, 2022 PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results Gross profit for the third quarter of 2022 was $13.5 million, repre
Read more →PACB▲ +9.4%on this news
PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15. Withdraws Guidance with New Product Announcement
PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15. Withdraws Guidance with New Product Announcement MENLO PARK, Calif., October 25, 2022 - PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call
Read more →PACB▲ +7.4%on this news· ran to +42% by day 3
PacBio Announces Second Quarter 2022 Financial Results Menlo Park, Calif. –
PacBio Announces Second Quarter 2022 Financial Results Menlo Park, Calif. August 3, 2022 PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2022. Second quarter results Gross profit for the second quarter of 2022 was $16.2 million, represent
Read more →PACB▲ +6.7%on this news· ran to -23% by day 3
PacBio Announces First Quarter 2022 Financial Results Menlo Park, Calif. –
PacBio Announces First Quarter 2022 Financial Results Menlo Park, Calif. May 4, 2022 PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2022. First quarter results "Our team continued to make progress expanding our installed base with our t
Read more →PACBPacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results Menlo Park, Calif. –
PacBio Announces Fourth Quarter and Fiscal Year 2021 Financial Results Menlo Park, Calif. February 15, 2022 PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last earnings release "Our record four
Read more →PACB▼ -11.3%on this news· ran to -25% by day 3
xFEFF; PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations MENLO PARK, Calif. –
PacBio Announces Record Preliminary Fourth Quarter 2021 Revenue, New Sequencing Kits and Workflows, and Expanded Collaborations MENLO PARK, Calif. January 11, 2022 PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced u
Read more →PACBPacBio Announces Third Quarter 2021 Financial Results Menlo Park, Calif. –
PacBio Announces Third Quarter 2021 Financial Results Menlo Park, Calif. November 2, 2021 PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2021. Record revenue reflects 6th straight quarter of sequential growth Gross profit for the th
Read more →PACBand broadly enable clinical sequencing; the potential ability of a combined product portfolio to deliver a differentiated set of products and applications across a broad spectrum of markets, including the clinical market
Pacific Biosciences Closes Acquisition of Omniome and Establishes San Diego Presence Omniome's high accuracy short-read sequencing platform expected to significantly expand PacBio's market opportunity Acquisition expected to accelerate the adoption of SMRT Sequencing, PacBio'
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Second Quarter 2021 Financial Results Menlo Park, Calif. August 3, 2021 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2021. Record second quarter revenue
Read more →PACB▲ +7.2%on this news
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome Combination aims to transform the genomics landscape and deliver a differentiated product offering into high growth clinical markets Brings together Omnio
Pacific Biosciences Signs Definitive Agreement to Acquire Omniome MENLO PARK, Calif. and SAN DIEGO, Calif, July 20, 2021 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (Nasdaq: PACB) ( Pacific Biosciences or PacBio ), a leading provider of high-quality, long-read sequ
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results Menlo Park, Calif. April 29, 2021 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021. Record first quarter revenue r
Read more →PACBPacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors
Pacific Biosciences Nominates Dr. Hannah Valantine to its Board of Directors MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr.
Read more →PACBPacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives Menlo Park, California
Pacific Biosciences Announces $900 Million Investment from SoftBank to Support Growth Initiatives Menlo Park, California February 10, 2021 Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the Company ), a leading provider of high-quality, long-read sequencing platforms,
Read more →PACBxFEFF; Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results Menlo Park, Calif. February 10, 2020 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31
Read more →PACBxFEFF; Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform New platform expected to make whole genome sequencing significantly more affordable and accessible for use
Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care MENLO PARK, Calif. January 13, 2021
Read more →PACBPacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue Menlo Park, Calif. January 11, 2021 Pacific Biosciences of California, Inc. (the Company ) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited
Read more →PACBxFEFF; Pacific Biosciences of California, Inc. Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer  Menlo Park, Calif. – January 8 , 2021 –
Pacific Biosciences of California, Inc. Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer Menlo Park, Calif. January 8, 2021 Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality s
Read more →PACBPacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock MENLO PARK, CA, November 10, 2020, Pacific Biosciences of California, Inc. (Nasdaq: PACB) ( Pacific Biosciences or the Company ) today announced that it has priced its previously announ
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2020 Financial Results Menlo Park, Calif. November 2, 2020 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Third Quarter 2020
Read more →PACBPacific Biosciences Announces New Chief Financial Officer
Pacific Biosciences Announces New Chief Financial Officer MENLO PARK, California, September 14, 2020 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announce
Read more →PACBxFEFF;   Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock 
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock MENLO PARK, CA, August 11, 2020, Pacific Biosciences of California, Inc. (Nasdaq: PACB) ( Pacific Biosciences or the Company ) today announced that it has priced its previously announced
Read more →PACBPacific Biosciences Announces New Chief Executive Officer Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim
Pacific Biosciences Announces New Chief Executive Officer Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO California, August 7, 2020 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (NASDA
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results Menlo Park, Calif. – August 3 , 2020 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financia
Pacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results Menlo Park, Calif. August 3, 2020 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Total revenue for the s
Read more →PACBxFEFF; Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller  Dr. Hunkapiller to retire by the end of 2020  Susan K. Barnes, CFO to retire in August 2020  
Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller Dr. Hunkapiller to retire by the end of 2020 Susan K. Barnes, CFO to retire in August 2020 MENLO PARK, California, June 10, 2020 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (NASDAQ: P
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 20 20 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results Menlo Park, Calif. May 6, 2020 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2020. As previously announced, in
Read more →PACBxFEFF;  Christian Henry Appointed Chairman of Pacific Biosciences' Board of Directors  MENLO PARK, Calif., March 5 , 2020 – Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider
Christian Henry Appointed Chairman of Pacific Biosciences' Board of Directors MENLO PARK, Calif., March 5, 2020 Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that in
Read more →PACBPacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development Dr. Denis Zaccarin Succeeds Phillips to Lead Research and Development
Pacific Biosciences Announces Retirement of Michael Phillips, SVP of Research and Development Dr. Denis Zaccarin Succeeds Phillips to Lead Research and Development MENLO PARK, Calif., Feb. 7, 2020 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading
Read more →PACBPacific Biosciences Announces Fourth Quarter and Annual 201 9 Financial Results Annual Revenue Increase of 16% Year Over Year Menlo Park, Calif. –
Pacific Biosciences Announces Fourth Quarter and Annual 2019 Financial Results Annual Revenue Increase of 16% Year Over Year Menlo Park, Calif. February 6, 2020 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and y
Read more →PACBIllumina and Pacific Biosciences Announce Termination of Merger Agreement SAN DIEGO &
Illumina and Pacific Biosciences Announce Termination of Merger Agreement SAN DIEGO & MENLO PARK, Calif. January 2, 2020 Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that they have mutually agreed to terminate their mer
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 201 9 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2019 Financial Results Menlo Park, Calif. November 7, 2019 Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the Company') today announced financial results for its third quarter ended September 30, 2019. The
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 201 9 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Second Quarter 2019 Financial Results Menlo Park, Calif. August 6, 2019 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2019. On April 24, 2019, the
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 201 9 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2019 Financial Results Menlo Park, Calif. May 3, 2019 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2019, as attached. During the fir
Read more →PACBPacific Biosciences Announces Fourth Quarter and Annual 201 8 Financial Results Menlo Park, Calif. –
Pacific Biosciences Announces Fourth Quarter and Annual 2018 Financial Results Menlo Park, Calif. February 11, 2019 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31, 2018, as attached. Dur
Read more →PACBIllumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery Brings Together Highly Accurate Short- and Long-Read Sequencing Tech
Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery SAN DIEGO & MENLO PARK, Calif. (BUSINESS WIRE) Nov. 1, 2018 Illumina, Inc. (NASDAQ: ILMN) and Pacific Biosciences (NASDAQ:PACB
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 201 8 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2018 Financial Results Menlo Park, Calif. November 1, 2018 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018. Total revenue for
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 201 8 Financial Results Menlo Park, Calif. – August 2, 201 8 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financi
Pacific Biosciences of California, Inc. Announces Second Quarter 2018 Financial Results Menlo Park, Calif. August 2, 2018 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2018. Total revenue for the s
Read more →PACBHenry Pacific Biosciences Appoints Christian Henry to Board of Directors Industry Veteran Previous Served as EVP & Chief Commercial Officer of Illumina 
Pacific Biosciences Appoints Christian Henry to Board of Directors Industry Veteran Previous Served as EVP & Chief Commercial Officer of Illumina MENLO PARK, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leading provider o
Read more →PACBPacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore
Pacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore Calif., May 8, 2018 Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that it has entered into a
Read more →PACBPacific Biosciences of California, Inc. Announces F irst Quarter 201 8 Financial Results  Menlo Park, Calif. – May 2, 201 8 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced f
Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results Menlo Park, Calif. May 2, 2018 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2018. Total revenue for the first
Read more →PACBPacific Biosciences Announces Fourth Quarter and Annual 2017 Financial Results Annual Product and Service Revenue Increases 19% Year over Year Menlo Park, Calif. –
Pacific Biosciences Announces Fourth Quarter and Annual 2017 Financial Results Annual Product and Service Revenue Increases 19% Year over Year Menlo Park, Calif. February 1, 2018 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fo
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.  Condensed Consolidated Balance Sheets (unaudited)         December 31, (in thousands, except p ar value ) 2
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets December 31, (in thousands, except p ar value ) 2017 2016 Assets Current assets Cash and cash equivalents $ 16,507 $ 16,765 Investments 46,365 55,213 Accounts receivable 13,433 11,4
Read more →PACBPacific Biosciences Appoints Kathy Ordo ez as Chief Commercial Officer
Pacific Biosciences Appoints Kathy Ordo ez as Chief Commercial Officer MENLO PARK, Calif., November 2, 2017 Pacific Biosciences of California, Inc. (NASDAQ:PACB) announced today that Kathy Ordo ez has been named Chief Commercial Officer and Executive Vice President. Ms. Ordo e
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 2017 Financial Results Product and Service Revenue Increases by 9 % Over Same Period in Previous Year  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2017 Financial Results Product and Service Revenue Increases by 9% Over Same Period in Previous Year Menlo Park, Calif. November 2, 2017 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financ
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results Product and Service Revenue Increases by 17 % Over Same Period in Previous Year  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results Product and Service Revenue Increases by 17% Over Same Period in Previous Year Menlo Park, Calif. August 2, 2017 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financ
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 2017 Financial Results Product and Service Revenue Increases by 60% Over Same Period in Previous Year  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2017 Financial Results Product and Service Revenue Increases by 60% Over Same Period in Previous Year Menlo Park, Calif. April 26, 2017 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financi
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.  Condensed Consolidated Balance Sheets (unaudited)            March 31, December 31,
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets March 31, December 31, (in thousands, except per share amounts) 2017 2016 Assets Current assets Cash and cash equivalents $ 28,982 $ 16,765 Investments 27,068 55,213 Accounts receivab
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC.  Consolidated Balance Sheets (unaudited)         December 31, (in thousands, except per share amounts) 2016
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets December 31, (in thousands, except per share amounts) 2016 2015 Assets Current assets Cash and cash equivalents $ 16,765 $ 33,629 Investments 55,213 48,641 Accounts receivable 11,421 5,245 In
Read more →PACBPacific Biosciences Announces Fourth Quarter 2016 Financial Results Product and Service Revenue Increases by 92% Over Same Period in Previous Year Menlo Park, Calif. –
Pacific Biosciences Announces Fourth Quarter 2016 Financial Results Product and Service Revenue Increases by 92% Over Same Period in Previous Year Menlo Park, Calif. February 2, 2017 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for it
Read more →PACBPacBio Announces Termination of Agreement with Roche Diagnostics
PacBio Announces Termination of Agreement with Roche Diagnostics MENLO PARK, California, December 15, 2016 Pacific Biosciences of California, Inc. (Nasdaq:PACB), today announced that F. Hoffman-La Roche Ltd (Roche) has elected to terminate for convenience the development, comme
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 2016 Financial Results Revenue Increases by 8 0 % Over Same Period in Previous Year  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2016 Financial Results Revenue Increases by 80% Over Same Period in Previous Year Menlo Park, Calif. November 2, 2016 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results Product and Service Revenue Increases by 51% Over Same Period in Previous Year  Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results Product and Service Revenue Increases by 51% Over Same Period in Previous Year Menlo Park, Calif. August 4, 2016 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financ
Read more →PACBPacific Biosciences of California, Inc. Announces F irst Quarter 201 6 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results Menlo Park, Calif. April 21, 2016 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2016. Revenue for the first qu
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets (unaudited) December 31, (in thousands, except per share amounts) 2015 2014 Assets Current assets Cash and cash equivalents $ 33,629 $ 36,449 Investment
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets December 31, (in thousands, except per share amounts) 2015 2014 Assets Current assets Cash and cash equivalents $ 33,629 $ 36,449 Investments 48,641 64,899 Accounts receivable 5,245 3,406 Inv
Read more →PACBPacific Biosciences Announces Fourth Quarter 2015 Financial Results Menlo Park, Calif. –
Pacific Biosciences Announces Fourth Quarter 2015 Financial Results Menlo Park, Calif. February 3, 2016 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter ended December 31, 2015. Revenue for the fourth quarter of 201
Read more →PACBPacific Biosciences Provides Update on Launch of New Sequel System Orders Received for 49 Sequel Systems in Q4 2015
Pacific Biosciences Provides Update on Launch of New Sequel System Orders Received for 49 Sequel Systems in Q4 2015 MENLO PARK, Calif., January 11, 2016 Pacific Biosciences of California, Inc. (Nasdaq:PACB), a pioneer and leader in long-read sequencing using its Single Molecul
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 201 5 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Third Quarter 2015 Financial Results Menlo Park, Calif. October 22, 2015 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2015. Revenue for the th
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets (Unaudited) September 30, December 31, (in thousands except par value amounts) 2015 2014 Assets Current assets Cash and cash equivalents $ 27,
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets September 30, December 31, (in thousands except par value amounts) 2015 2014 Assets Current assets Cash and cash equivalents $ 27,208 $ 36,449 Investments 31,701 64,899 Accounts
Read more →PACBPacific Biosciences Launches New Sequencing Platform Based on its SMRT Technology Sequel ™ System Offers Significantly Higher Throughput, Reducing Project Costs and Timelines MENLO PARK, Calif. ȁ
Pacific Biosciences Launches New Sequencing Platform Based on its SMRT Technology Sequel System Offers Significantly Higher Throughput, Reducing Project Costs and Timelines MENLO PARK, Calif. September 30, 2015 Pacific Biosciences of California, Inc., (NASDAQ:PACB) a pioneer an
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 201 5 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces Second Quarter 2015 Financial Results Menlo Park, Calif. August 5, 2015 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported a 118% increase in revenue with $24.9 million for the second quarter ended June 30, 201
Read more →PACBPacific Biosciences Achieves Second Development Milestone in Clinical Diagnostics Agreement with Roche $10 Million Milestone Payment Brings Total Funding to Date from Roche up to $55 Million MENLO PARK, Calif., –
Pacific Biosciences Achieves Second Development Milestone in Clinical Diagnostics Agreement with Roche $10 Million Milestone Payment Brings Total Funding to Date from Roche up to $55 Million MENLO PARK, Calif., May 5, 2015 Pacific Biosciences of California, Inc. (Nasdaq:PACB),
Read more →PACBPacific Biosciences of California, Inc. Announces F irst Quarter 201 5 Financial Results Menlo Park, Calif. –
Pacific Biosciences of California, Inc. Announces First Quarter 2015 Financial Results Menlo Park, Calif. May 5, 2015 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported a 52% increase in revenue with $17.6 million for the first quarter ended March 31, 2015, co
Read more →PACBPacific Biosciences Reports Fourth Quarter 201 4 Financial Results Menlo Park, Calif. – February 3, 201 5 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported a n 8 5 % increase in revenu
Pacific Biosciences Reports Fourth Quarter 2014 Financial Results Menlo Park, Calif. February 3, 2015 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported an 85% increase in revenue to $16.9 million for the fourth quarter ended December 31, 2014, compared to $9.
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets (unaudited) December 31, (in thousands, except per share amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 36,449 $ 26,362 Investment
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets December 31, (in thousands, except per share amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 36,449 $ 26,362 Investments 64,899 86,166 Accounts receivable 3,406 2,746 Inv
Read more →PACBPacific Biosciences Appoints Kathy Ordoñez to Board of Directors Industry Veteran Previously Served as SVP at Quest Diagnostics and CEO of Celera and of Roche Molecular Systems MENLO PARK, California, USA –
Pacific Biosciences Appoints Kathy Ordo ez to Board of Directors Industry Veteran Previously Served as SVP at Quest Diagnostics and CEO of Celera and of Roche Molecular Systems MENLO PARK, California, USA December 18, 2014 Pacific Biosciences of California, Inc., (Nasdaq:PACB)
Read more →PACBPacific Biosciences Reports Third Quarter 201 4 Financial Results Menlo Park, Calif. –
Pacific Biosciences Reports Third Quarter 2014 Financial Results Menlo Park, Calif. October 23, 2014 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported a 178% increase in revenue to $20.6 million for the third quarter ended September 30, 2014, compared to $7.4
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets (Unaudited) September 30, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 35,
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets September 30, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 35,411 $ 26,362 Investments 63,901 86,166 Accounts recei
Read more →PACBPacific Biosciences Reports Second Quarter 201 4 Financial Results Menlo Park, Calif. – July 24 , 201 4 – Pacific Bioscie nces of California, Inc. (NASDAQ : PACB) today reported an 89% increase in revenue t
Pacific Biosciences Reports Second Quarter 2014 Financial Results Menlo Park, Calif. July 24, 2014 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today reported an 89% increase in revenue to $11.4 million for the second quarter, compared to $6.0 million for the second qu
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets (Unaudited) June 30, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 28,200 $
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets June 30, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 28,200 $ 26,362 Investments 76,834 86,166 Accounts receivable
Read more →PACBPacific Biosciences of California, Inc. Announces F irst Quarter 201 4 Financial Results Menlo Park, Calif. – April 30 , 201 4 – Pacific Bioscie nces of California, Inc. (NASDAQ : PACB) today annou nced fin
Pacific Biosciences of California, Inc. Announces First Quarter 2014 Financial Results Menlo Park, Calif. April 30, 2014 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2014. Revenue for the first qu
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets (Unaudited) March 31, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 41,261
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets March 31, December 31, (in thousands except par value amounts) 2014 2013 Assets Current assets Cash and cash equivalents $ 41,261 $ 26,362 Investments 77,475 86,166 Accounts receivabl
Read more →PACBPacific Biosciences of California, Inc. Announces Fourth Quarter 2013 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Fourth Quarter 2013 Financial Results Menlo Park, Calif. February 4, 2014 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the fourth quarter ended December 31, 2013. Total revenue f
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets (Unaudited) December 31, (in thousands, except per share amounts) 2013 2012 Assets Current assets Cash and cash equivalents $ 26,362 $ 46,540 Investment
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets December 31, (in thousands, except per share amounts) 2013 2012 Assets Current assets Cash and cash equivalents $ 26,362 $ 46,540 Investments 86,166 54,040 Accounts receivable
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 2013 Financial Results Menlo Park, Calif. – October 2 2 , 201 3 – Pacific Bioscie nces of California, Inc. (NASDAQ : PACB) today annou nced fi
Pacific Biosciences of California, Inc. Announces Third Quarter 2013 Financial Results Menlo Park, Calif. October 22, 2013 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the third quarter ended September 30, 2013. Total revenue for
Read more →PACBPacific Biosciences Announces Agreement with Roche Diagnostics to Develop and Supply DNA Sequencing-Based Products for Clinical Diagnostics MENLO PARK, Calif. —
Pacific Biosciences Announces Agreement with Roche Diagnostics to Develop and Supply DNA Sequencing-Based Products for Clinical Diagnostics MENLO PARK, Calif. September 25, 2013 Pacific Biosciences of California, Inc., (NASDAQ:PACB), provider of the PacBio RS II DNA Sequencing S
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2013 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. August 1, 2013 Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the second quarter ended June 30, 2013. Revenue for the second quarter of 2013 totaled $6.0 million
Read more →PACBPacific Biosciences Appoints John F. Milligan to Board of Directors Gilead Sciences Executive Recognized for Financial Leadership in Biotech Industry
Pacific Biosciences Appoints John F. Milligan to Board of Directors Gilead Sciences Executive Recognized for Financial Leadership in Biotech Industry MENLO PARK, Calif. July 18, 2013 Pacific Biosciences of California, Inc. (NASDAQ:PACB), provider of the PacBio RS II DNA Sequen
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 2013 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. April 23, 2013 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the first quarter ended March 31, 2013. During the first quarter of 2013, the Company recognized re
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands except per share amounts)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Condensed Consolidated Balance (in thousands except per share amounts) March 31, 2013 December 31, 2012 Assets Current assets Cash and cash equivalents $ 53,038 $ 46,540 Investments 59,267 54,040 Accounts rec
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets (Unaudited) (in thousands except per share amounts)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Consolidated Balance Sheets (in thousands except per share amounts) December 31, 2012 December 31, 2011 Assets Current assets Cash and cash equivalents $ 46,540 $ 58,865 Investments 54,040 118,569 Accounts re
Read more →PACBPacific Biosciences Completes $20.5 Million Debt Financing Menlo Park, Calif.
Pacific Biosciences Completes $20.5 Million Debt Financing Park, Calif., February 5, 2013 (GLOBE NEWSWIRE) Pacific Biosciences of California, Inc. (Nasdaq:PACB) provider of the PacBio RS High Resolution Genetic Analyzer, today announced that it has entered into an agreement with
Read more →PACBPacific Biosciences of California, Inc. Announces Fourth Quarter 2012 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. February 5, 2013 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the fourth quarter ended December 31, 2012. During the fourth quarter of 2012, the Company recogn
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter 2012 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. October 25, 2012 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the third quarter ended September 30, 2012. During the third quarter of 2012, the Company recogni
Read more →PACBPacific Biosciences Appoints Lucy Shapiro, Ph.D. to Board of Directors
Pacific Biosciences Appoints Lucy Shapiro, Ph.D. to Board of Directors MENLO PARK, Calif., September 12, 2012 Pacific Biosciences of California, Inc. (NASDAQ:PACB) provider of the PacBio RS High Resolution Genetic Analyzer, today announced that renowned scientist Lucy Shapiro,
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter 2012 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. July 26, 2012 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the second quarter ended June 30, 2012. During the second quarter of 2012, the Company recognized re
Read more →PACBPacific Biosciences Names David Botstein, Ph.D. to its Board of Directors
Pacific Biosciences Names David Botstein, Ph.D. to its Board of Directors MENLO PARK, Calif., July 23, 2012 Pacific Biosciences of California, Inc. (NASDAQ:PACB) provider of the PacBio RS High Resolution Genetic Analyzer, today announced the appointment of David Botstein, Ph.D.,
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter 2012 Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. May 1, 2012 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the first quarter ended March 31, 2012. During the first quarter of 2012, the Company recognized reven
Read more →PACBPacific Biosciences of California, Inc. Announces Financial Results for the Fourth Quarter and Year Ended
Pacific Biosciences of California, Inc. Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2011 Menlo Park, Calif. February 7, 2012 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the fourth quarter and
Read more →PACBPacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer
Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer MENLO PARK, Calif. January 6, 2012 Pacific Biosciences of California, Inc. (NASDAQ:PACB), provider of Single Molecule Real Time (SMRT ) sequencing products, today announced the appointment of Michael W. Hun
Read more →PACBPacific Biosciences of California, Inc. Announces Third Quarter Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. October 27, 2011 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the third quarter ended September 30, 2011. During the third quarter of 2011, the Company recogni
Read more →PACBPacific Biosciences of California, Inc. Announces Second Quarter Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces Menlo Park, Calif. August 4, 2011 Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the second quarter ended June 30, 2011. Second Quarter 2011 Financial Results: During the second qu
Read more →PACBPacific Biosciences of California, Inc. Announces First Quarter Financial Results Menlo Park, Calif.
Pacific Biosciences of California, Inc. Announces First Quarter Financial Results Menlo Park, Calif. - April 27, 2011 - (Globe Newswire) Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the quarter ended March 31, 2011. First Quarter
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2010 OPERATING RESULTS Menlo Park, Calif.
PACIFIC BIOSCIENCES OF CALIFORNIA ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2010 OPERATING RESULTS Menlo Park, Calif., February 15, 2011 (Globe Newswire) Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the fourth quarter and fiscal yea
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA ANNOUNCES THIRD QUARTER OF 2010 OPERATING RESULTS Menlo Park, Calif.
PACIFIC BIOSCIENCES OF CALIFORNIA ANNOUNCES THIRD QUARTER OF 2010 OPERATING RESULTS Park, Calif., Nov. 30, 2010 (Globe Newswire) Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced financial results for the third quarter ended September 30, 2010. Financial Hi
Read more →Competitive Position
How PACB ranks across every disease it competes inCompetitive Position is a premium feature
See how PACB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial